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ABSTRACT 
The emergence and spread of parasites resistant to first-line antimalarial drugs comprising 
artemisinin combination therapies (ACTs) threaten malaria control. There is therefore a 
need to develop novel and chemically diverse alternatives that are safe, efficacious, and 
able to circumvent drug resistance.  
Schistosomiasis is the second most prevalent tropical disease in the world after malaria, and 
treatment relies on a single drug: praziquantel. Although praziquantel shows multiple 
benefits over drugs previously used to treat schistosomiasis, dependence on it will result in 
therapeutic limitations and drug resistance threats. Therefore, there is a dire need to 
develop novel antischistosomal drugs that are eﬀective and aﬀordable. 
One attractive approach to accelerate the drug discovery and development process is the 
exploration of current drugs and drug leads as probable therapies for other diseases. This 
strategy is known as drug repurposing or drug repositioning, of which the latter is applied in 
this research project. The cytological similarities in the degradation of haemoglobin 
performed by Plasmodium parasites and Schistosoma blood flukes in malaria and 
schistosomiasis, respectively, suggest an opportunity for the repositioning of antimalarial 
scaffolds as antischistosomal agents. 
Pyrido[1,2-a]benzimidazoles (PBIs) demonstrate various biological and pharmacological 
properties such as anti-inflammatory, analgesic, antimicrobial, antiviral, and antineoplastic 
activities. More recently, PBI derivatives showed favourable in vitro activities against both 
Plasmodium falciparum and adult Schistosoma mansoni, but modest in vivo potencies. 
Pharmacokinetic analysis suggests that the sub-optimal in vivo efficacy of PBIs is related to 
solubility-limited absorption and poor metabolic stability. With the aim of circumventing 
these challenges, structural modifications have been employed to explore structure-activity 
and structure-property relationships to produce target compounds with improved drug-
likeness (Figure A). 
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Figure A: Structure-activity explorations around lead compound TDR44047, resulting in 
compound 33, which showed improved solubility and antiplasmodium activity against 
Plasmodium falciparum (Pf) NF54 
This study aimed to expand the SAR by performing chemical modifications on the PBI 
scaffold with the purpose of maintaining or improving biological activity, and to address 
solubility-limited absorption challenges with this series of compounds (Figure A). The 
synthesized derivatives were tested against the chloroquine-sensitive (NF54) strain of P. 
falciparum and against adult S. mansoni concurrently. The most active compound in this PBI 
series, a di-fluoro-substituted derivative composed of a cyclohexyl piperazine side-chain 
(33), showed improved in vitro activity against the NF54 strain of P. falciparum (IC50 = 0.012 
µM) and enhanced solubility (Figure A). Compounds with methylene or ethylene linkers at 
the R1 position (Figure A) showed comparable potency, although the directly linked phenyl 
piperazine analogue showed poor antiplasmodium activity. Compounds containing 
hydrophobic electron-withdrawing fluoro, chloro, and trifluoromethyl Craig plot 
substituents at the para position of the phenyl group showed enhanced antiplasmodium 
activity compared to those containing hydrophobic electron-releasing methyl groups and 
hydrophilic electron-withdrawing cyano groups. In the LHS-unsubstituted series of 
compounds, regio-isomerism at substituent R2 (Figure A) resulted in comparable 
antiplasmodium activity, and this observation was maintained with LHS-substituted PBI 
derivatives. Notably, unsubstituted derivatives and di-substituted groups displayed 
moderate to high antiplasmodium potency. Mechanistic evaluations of the compounds 
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revealed non-existent to weak correlations between antiplasmodium activities and their 
potential to inhibit hemozoin (Hz) formation. This suggests that Hz inhibition is not the sole 
target of this class of compounds, although it may be a contributory mode of action. 
Compounds were also screened at 10 µM against newly transformed schistosomula and 
adult S. mansoni. Two compounds showed high antischistosomal activity against both larval 
and adult parasites, resulting in > 70% inhibition of worm viability. 
A turbidimetric assay was carried out to assess the solubility of target PBI compounds. In 
most cases, the synthesized compounds displayed high in vitro activities and slight 
improvements in solubility. This therefore encourages further optimization of piperazinyl 
PBI compounds to improve efficacy and solubility.  
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 Malaria 1.1
1.1.1 Etiology and epidemiology 
In 2016, the World Health Organization reported approximately 216 million malaria 
cases and over 440 000 malaria deaths worldwide.1 The mosquitoes responsible for malaria 
in humans are the 40 species of infected female Anopheles mosquitoes, which through a 
bite, transmit protozoa of the genus, Plasmodium.2 These parasitic protozoans are of the 
sporozoan sub-class Coccidia. They infect red blood cells in humans and survive best in 
tropical and temperate zones.2 
 
The 1907 Nobel Prize winner Charles Louis Alphonse Laveran was the first person to 
discover the malaria parasite in the blood sample of a malaria infected patient.2,3 Six years 
after this discovery, Camillo Golgi, a neurophysiologist  1906 Nobel Prize winner established 
that two species of malaria parasites existed and hence two forms of the disease.3,4 In the 
one form of the disease, patients experienced fever every other day (tertian periodicity) and 
the other was associated with fever every third day (quartan periodicity). These two forms 
also produced different numbers of merozoites upon maturity and the fever was as a result 
of the rupture and release of merozoites into the blood stream of the infected host.3  
 
To date, there are five known plasmodium species that cause the disease: P. falciparum, P. 
vivax, P. ovale, P. malariae and P. knowlesi. These species are distributed in various regions, 
dependent on ecological and behavioural parameters that affect the infected mosquito’s 
ability to transmit the plasmodium parasite. Plasmodium falciparum is common in the 
tropical regions of Sub-Saharan Africa, South East Asia, Oceania and certain areas of South 
America (Figure 1). It is responsible for majority of infections and causes the most severe 
form of malaria. 
 
Plasmodium vivax, another virulent protozoa, is widespread primarily in Asia, America, 
certain areas of Eastern Europe and North Africa. This species has a broader geographical 
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distribution compared to P. falciparum, because of its ability to withstand low temperatures 
and high altitudes. Despite this wide geographical distribution, majority of cases occur in 
Ethiopia, India and Pakistan. Plasmodium  ovale is found mainly in tropical western and 
central Africa and islands in the West Pacific. It is similar to P. vivax in that it also has a 
dormant liver stage which can reactivate, resulting in relapse (recurrence of infection from 
hypnozoites). Plasmodium  malariae and P. knowlesi are found in areas where P. falciparum 
is distributed, however, they are less prevalent.5 
 
Figure 1: World map showing malaria hotspots6 
There are several risk factors for infection including: travel to malaria endemic regions; poor 
malaria chemoprevention measures; settled migrants relocating to their country of origin- 
where malaria is endemic; low host-immunity individuals (majorly affecting those who live 
in non-endemic regions) and immunocompromised patients with weakened immune 
systems. In regions with high malaria transmission rates, pregnant women and young 
children (especially under the age of 5 years) are the most vulnerable groups.1,7 
1.1.2 Life cycle and pathogenesis  
The malaria transmission cycle involves two types of hosts: humans and female Anopheles 
mosquitoes. The female Anopheles mosquito acts as a vector and harbors the plasmodium 
parasite, which, via biting a human, injects plasmodial sporozoites, which rapidly make their 
way to the human host liver and infect hepatocytes.2 The sporozoites develop into liver 
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schizonts and further rupture to release thousands of merozoites into the human blood. In 
the case of P. vivax and P. ovale, a dormant stage (hypnozoites) may occur in the liver and 
results in relapses. After replication of the parasite in the liver, asexual multiplication occurs 
in the erythrocytes and the released merozoites invade red blood cells. The parasite 
progresses through the ring stage, develops into trophozoites and later mature into 
schizonts, which burst to release more merozoites, thereby repeating the erythrocytic 
infection cycle2,8 (Figure 2). 
 
Figure 2:  Malaria life cycle of plasmodium parasites9 
The blood stage parasites are responsible for the clinical symptoms of malaria. During the 
erythrocytic cycle, some parasites differentiate into male microgametocytes and female 
macrogametocytes (the sexual forms of the parasite). Once taken up by the mosquito, the 
gametocytes fertilize within the mosquito’s gut, undergoes meiosis and then migrates 
through the midgut wall to form an oocyst, within which sporozoites develop and are 
inoculated into the human host, continuing the transmission cycle2,8 (Figure 2).  
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1.1.3  Chemotherapy and challenges in malaria treatment 
Malaria is preventable and if contracted, with timely diagnosis, is also curable. The 
treatment prescribed to a malaria infected patient is usually based on several factors 
including: the Plasmodium parasite species causing the infection; the health status of the 
patient and severity of the disease; the drug susceptibility of the Plasmodium parasite 
subject to local and regional resistance patterns; and lastly the risk groups, which include 
children under the age of 5, pregnant women and non-immune travelers.10,11  
 
Despite the availability of malaria treatment, there has been the major concern of drug 
resistance where previously effective antimalarial drugs such as chloroquine and 
pyrimethamine/sulfadoxine (Figure 3) are compromised by the development of drug 
resistant parasites.12  
 
Novel drug regimens such as artemisinin-combination therapies (ACTs) have been 
remarkably effective in treating malaria forms resistant to the aforementioned drugs.5 
Artemisinin analogs are fast-acting and potent antimalarial drugs that perform poorly as 
single agents against P. falciparum due to their rapid elimination. However, in combination 
with other antimalarial agents, artemisinin derivatives have shown impressive efficacy. ACTs 
consist of an artemisinin derivative (fast-acting), e.g., artemether in combination with a 
longer-acting blood schizonticide e.g., lumefantrine, amodiaquine, 
sulfadoxine/pyrimethamine, piperaquine and are, at present, the first line treatment for 
most malaria infections.13 However, recent reports have shown signs of emerging parasite 
resistance to ACTs in South-East Asia.14,15 As a result, research and development is necessary 
to develop antimalarial drugs that are safe, potent against drug resistant strains of the 
Plasmodium parasite and affordable to benefit the affected larger deprived community.  
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Figure 3: Artemisinin and its various semi-synthetic derivatives and other examples of 
antimalarial drugs in clinical use 
The optimization and improvement of existing drugs through chemical modification 
approaches have shown various successes in malaria drug development and this strategy is 
responsible for many existing antimalarial agents.16,17  
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Figure 4: Examples of some successful chemical modifications 
Quinine is a good example of a drug that was improved by employing chemical modification 
in a malarial context. Chloroquine, primaquine and mefloquine were optimized from quinine 
through chemical modification strategies18 (Figure 4). Another good example is tafenoquine, 
an 8-aminoquinoline which, compared to the parent compound primaquine, showed 
enhanced activity against hepatic-stage parasites. Lumefantrine, a drug used in combination 
with artemether was adapted from halofantrine, which was linked to fatal cardiotoxicity.16,17 
1.1.4 Current Drug Pipeline  
Drug candidates undergo different phases of development in the pipeline before they can 
be approved. Pre-clinical assessment involves the examination of the potential drug in non-
humans to study the efficacy, toxicity of the candidate drug as well as the pharmacokinetics 
(oral bioavailability and half-life) of the drug. If the drug candidate successfully passes 
through this stage, it undergoes phase 1 clinical trials. During Phase 1 trials, the promising 
drug is investigated on normal healthy volunteers for dose-range finding. After the drug has 
progressed from phase 1, it is examined in phase 2 on patients (approximately 100-300) to 
carefully study the efficacy and side effects of the candidate drug. During phase 3 clinical 
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trials, the efficacy and safety of the potential drug candidate is assessed on a larger group of 
patients (about 300-1000). Candidate drugs may fail at different stages of the drug 
development pipeline, however, drugs that progress successfully past phase III clinical trials, 
are approved.19,20 
 
Figure 5: Current Malaria Drug Pipeline (Medicines  for Malaria Venture, MMV) highlighting 
the various drug candidates at different stages of development21 
The drug development pipeline includes projects focused on developing novel drugs or drug 
regimens for different patient populations. A good example is the development of a 
pediatric formulation of coartem (artemether-lumefantrine combination), the first example 
of a child-friendly taste-masked dispersible ACT22 (Figure 5). Pyronaridine-artesunate and 
dispersible dihydroartemisinin (DHA)-piperaquine (Figure 6) are approved antimalarial ACT 
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 Sulfadoxine- 
pyrimethamine+  
amodiaquine 
dispersible 
 Artemether-
Lumefantrine 
dispersible 
 Artesunate for injection 
 Dihydroartemisinin-
piperaquine 
 Pyronaridine-
artesunate 
 Pyronaridine-
artesunate granules 
 Artesunate-
amodiaquine 
 Artesunate-mefloquine 
 Sulfadoxine-
pyrimethamine+amodia
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drug candidates (Figure 5). These are aimed at delivering child-friendly formulations to cater 
for the extremely high malaria cases in children under the age of five.23,24 
 
Figure 6: Structures of some phase I, phase II and approved drug candidates in the MMV 
Malaria Drug Development Pipeline 
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The Global Malaria Agenda aims to control, eliminate and eradicate the malaria burden25 via 
various strategies: optimization of current chemotherapy, single-exposure radical cure 
(SERC) and single-exposure chemoprotection (SEC).26,27 These strategies aim to reduce 
mortality and morbidity rates in endemic settings, block transmission from symptomatic and 
asymptomatic individuals in order to protect uninfected individuals and consequently 
reduce malaria incidences. These aims can be achieved through the development of 
antimalarial agents that are effective against resistant Plasmodium parasites and inventing 
drugs that cater for the vulnerable populations.28 The SERC agenda targets improving the 
convenience of administration, making the antimalarial drug affordable so that it benefits 
the highly affected communities in resource-poor settings. The SEC program focuses on the 
development of new antimalarial drugs that target novel pathophysiology in order to 
forestall development of resistance and ensure that the antimalarials are safe and effective 
with minimal adverse effects.26,27 
 
The MMV manages a portfolio of many malaria related projects and currently includes nine 
new drug candidates in clinical development. This portfolio focuses on the development of 
new drugs aimed at addressing unmet medical needs in malaria treatment for the 
vulnerable young children, pregnant women and for relapsing malaria and relevant projects 
whose objective is to eliminate malaria.20,25,28 Cipargamin, currently in phase II clinical 
development (Figure 5) is hoped to function in severe malaria cases.29,30 The 
KAF156/Lumefantrine combination drug candidate (Figure 6) for malaria treatment has an 
unknown mechanism of action, however, has also demonstrated desired potency against 
parasites that are resistant to current drugs.31 Although DSM265 has reduced activity 
against P. vivax and due to its single enzyme target, is likely to suffer resistance, DSM265 is a 
potential chemoprotective agent32,33 (Figure 6). The MMV390048, an inhibitor 
of Plasmodium phosphatidylinositol 4-kinase is an aminopyridine derivative (Figure 6)  that 
has undergone preclinical development, completed phase 1 human trials and has shown 
potency against multiple parasite life cycle stages.34 The P. falciparum EF2 inhibitor, M5717 
is undergoing clinical development and has demonstrated desirable potential to address 
various clinical needs, for example: single-dose treatment, transmission blocking and 
chemoprotection.35 P218 is a P. falciparum dihydrofolate reductase inhibitor that has 
recently completed its first-in-human study36,37 (Figure 6). 
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Advances in antimalarial research and development are important for the world's future 
ability to treat and control malaria. Unfortunately, malaria being a disease of poverty, the 
business-driven industrial antimalarial drug research due to the inadequate market 
incentive, is not competitive and, therefore, efforts into research in this disease area are 
minimal. 38 However, some mechanisms of partnering with industry have been implemented 
for improvement and the enhancement of scientific research into better chemotherapy. 5 
1.1.5 Chemoprophylaxis 
The use of antimalarials as chemoprophylactic agents is useful for tourists visiting malaria 
endemic areas - mefloquine, doxycycline and primaquine (Figure 7) are the common drugs 
taken for this effect. Chloroquine also has potential to serve as a malaria prophylactic drug, 
but can only be effective in regions that are unaffected by P. falciparum and in regions 
where this species is not yet resistant to the drug.39,40  
 
Figure 7: Examples of malaria chemoprophylactic agents 
Although malaria is common in developing countries, it has a global impact in that about 
half of the world’s population are at risk of being infected. This raises the need for global 
attention to reduce the prevalence and impact of malaria by implementing approaches such 
as vector control, chemoprophylaxis, and chemotherapy.41 
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 Schistosomiasis 1.2
1.2.1 Etiology and epidemiology 
Schistosomiasis also known as bilharzia or snail fever is a water-borne parasitic disease 
caused by trematode flatworms of the genus Schistosoma species. S. haematobium, S. 
mansoni, S.  intercalatum, S. guineensis, S. japonicum, and S. mekongi species infect humans 
and cause illness.42  
 
After malaria, schistosomiasis is the second most prevalent tropical disease in the world, a 
major source of morbidity and mortality for many developing countries in Africa, South 
America, the Caribbean, the Middle East and Asia43 (Figure 8). Schistosomiasis affects over 
200 million people and over 700 million are at risk of infection. The endemic areas are 
commonly in tropical and sub-tropical regions and in communities that lack proper 
sanitation.44,45 
 
Figure 8: World Map showing schistosomiasis hotspots46 
There are two main types of schistosomiasis: genitourinary and intestinal, whose occurrence 
is dependent on the Schistosoma parasitic species causing the infection.47 Table 1 shows the 
two types of shistosomiasis that exist, the form that each schistosoma species causes and 
the geographical distribution of schistosomiasis in each category. 
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Table 1: Geographical distribution of Schistosoma species. 
Schistosoma 
species 
Type of 
schistosomiasis 
Geographical distribution 
S. haematobium Urogenital Africa, the Middle-East, India, and Turkey 
S. mansoni Intestinal Africa, the Middle-East, the Caribbean, South-America 
S. japonicum Intestinal South-east and East Africa 
S. mekongi Intestinal Cambodia and Laos 
S. intercalatum Intestinal Central and West Africa 
S. guineensis Intestinal Central and West Africa 
 
A human is infected with schistosomiasis when the cercariae of parasite blood flukes 
(schistosomes), released by freshwater snails penetrate the human skin during exposure to 
contaminated freshwater. In the body of the infected hosts, the larval forms develop into 
adult schistosomes.45,48 These male and female worms reside in various locations in the 
mesenteric venules and is in some way species-specific. For instance, S. japonicum and S. 
mekongi are frequently found in the mesenteric venules of the small intestines whereas S. 
mansoni and S. intercalatum are commonly found in the mesenteric venules of the large 
intestines. S. haematobium on the other hand, resides in the vesical venous plexus of the 
bladder or the rectal venules and is the reason it causes urogenital schistosomiasis (Table 
1).43,48 
1.2.2 Life cycle and pathogenesis 
Similar to other trematodes, schistosomiasis has a very complex life-cycle, which involves 
two hosts: the intermediate (snail) and the definitive (mammalian) hosts. It is acquired via 
skin exposure to contaminated water infested with cercariae (parasitic larvae). The cercariae 
are free-living in contaminated freshwater and are released by the specific snail 
intermediate host which then with the aid of proteolytic enzymes swim and penetrate the 
human skin.43,45 Upon penetration, the cercariae sheds off its tail and transform into 
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schistosomulae, which via portal blood circulation to the liver mature into male and female 
worms. During the hosts circulation, the thread-like female worm attaches to the 
gynecophoric canal (a ventral groove) of the male schistosome fluke, migrate to the venous 
plexus or the mesenteric venules in various locations, where the female schistosomes begin 
egg production. The eggs circulate and penetrate the wall of the lumen of the intestine or 
the bladder and are then expelled in the faeces or urine of the definitive host. The 
miracidium, liberated from the eggs then seek out the intermediate snail host, bringing the 
transmission cycle full circle43,45,48,49 (Figure 9). 
 
Figure 9: Schistosomiasis life cycle50 
1.2.3 Chemotherapy and challenges in schistosomiasis treatment 
Schistosomiasis is a neglected tropical disease (NTD). The NTDs are infectious diseases that, 
even though are treatable and preventable, still cause high rates of morbidity and mortality. 
These diseases are more prevalent in developing countries, affecting the poor, and causing 
significant health and financial burdens.  
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The development of drugs against these diseases to clinical stages is heavily neglected: out 
of the many potential drugs that register for clinical trials only a few are focused on NTDs. 
This is due to the very low research investment for NTDs compared to first world diseases 
such as cardiovascular and central nervous system diseases. Fortunately, the situation is 
changing, having more pharmaceutical companies and other development partners commit 
to contributing to the eradication and control of NTD researches. 
 
Most patients suffering from schistosomiasis rely on one drug, praziquantel, for treatment 
and because of this; there are therapeutic limitations and drug resistance threats. This 
highlights the urgent need to discover and develop novel antischistosomal drugs. In one 
example of a drug discovery effort, a diverse compound with in vitro activity against 
Plasmodium falciparum discovered by the MMV were tested against schistosomula and 
adult S. mansoni in vitro.51 Based on the obtained in vitro results, favourable compounds 
were further investigated in vivo. This work identified two potential leads: N,N'-diarylurea 
(MMV665852) and 2,3-dianilinoquinoxaline (MMV007224) derivatives (Figure 10), that were 
found active against S. mansoni, reducing worm burden by 52.5% and 40.8%, respectively. 
The two leads displayed satisfactory pharmacokinetic profiles, low cytotoxic potential and 
thus are a good foundation for further antischistosomal drug discovery and development 
studies.42,51 
 
Figure 10: Potential antischistosomal early leads identified from the open access MMV 
malaria box 
Praziquantel (Figure 11) is the preferred drug prescription for the treatment of 
schistosomiasis. There are other drugs (oxamniquine and metrifonate; Figure 11) that can 
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be used for treatment. However, unlike praziquantel that cures all forms of schistosomiasis, 
these drug options have exclusive efficacy and are limited to specific Schistosoma species (S. 
mansoni and S. haematobium, respectively). The dependence on only one drug, 
praziquantel, for its ability to treat all forms of the disease may potentially result in drug 
resistance, highlighting the need to develop new drugs that are as effective and affordable 
as praziquantel.52,53  
 
Figure 11: Drugs currently used to treat schistosomiasis 
Despite the success of praziquantel as an antichistosomal agent, it also has several 
shortcomings. Firstly, it is commercially available as a racemic mixture of the L and D 
isomers and yet only the L-isomer is active.53 Secondly, praziquantel has a bitter taste which 
may affect medical compliance. Lastly, the biggest problem is its limited activity against 
adult schistosomes only and its failure to treat the juvenile stages of the flukes.54 
 Approaches to Antimalarial and Antischistosomal Drug 1.3
Discovery 
1.3.1 Introduction 
As already mentioned, malaria is an infectious disease killing hundreds of thousands of 
people every year. The increasing resistance of malaria parasites to current chemotherapy is 
a major contributor to malarial mortality and morbidity. Also, in the case of schistosomiasis, 
the reliance on praziquantel for treatment for its ability to treat all forms of the disease 
raises legitimate resistance concerns. Resistance is a major challenge and is addressed by 
various drug development strategies.55,56  
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Common to many drug development programs, antimalarial and antischistosomal drug 
development programs aim to introduce new agents with improved efficacy and safety.57 
More specific to malaria and schistosomiasis, is the need for widespread treatment in 
developing countries considering the lack of resources in these affected areas, oral drugs 
and more specifically single daily dosing. These efforts are crucial in this setting to make 
these novel drugs widely useful, affordable and routinely available to majority of the 
affected population.16 
 
Approaches to drug discovery and development range from strategies that benefit from 
understanding specific aspects of the biology of parasites to making chemical modifications 
to generate new compounds.16,58 
1.3.2 Target-based screening versus Phenotypic whole-cell screening 
Target-based screening and phenotypic screening are competing strategies for drug 
discovery. Target-based screening is a molecular hypothesis-driven approach. It makes use 
of known drug targets (e.g. enzymes) against which compounds are screened for hit 
compound identification.  A requirement for this procedure is that the known parasitic drug 
target needs to be validated.59 There are four levels of validation. First, target essentiality 
must be validated by determining the effect of disrupting function or diminishing expression 
in an organism on proliferation in culture or in the host. Second, phenotypic validation, 
defined as a chemical compound inhibiting an enzyme target and also demonstrating an 
effect on the organism (most often cell kill), must be demonstrated. Third, in vivo validation, 
also known as in vivo proof-of-concept (POC), which refers to the capability of a compound 
to create the intended pharmacodynamic (PD) effect in an animal model, must be achieved. 
For an antimalarial drug, this most often is the reduction of parasitemia in a mouse model of 
infection. To show efficacy, the compound needs favourable in vivo pharmacokinetic (PK) 
properties for sufficient exposure in the blood to produce the intended PD response. 
Fourth, clinical validation represents the most important level of validation. To achieve 
clinical validation, the human PK must be favourable, whether it would be exposure in the 
blood for asexual stages of the malaria parasite or in the liver for liver stage disease.59,60 
 
17 
 
Advances in recombinant technology, genetics and molecular biology have improved target-
based drug discovery significantly: genes can be expressed and examined against large 
compound libraries via high-throughput screening (HTS). However, hit compounds obtained 
from this approach often result in poor in vivo efficacy, likely due to the expected 
physiological differences between the identified target and the biological system.61,62 
 
Unlike target-based approaches, phenotypic whole-cell screening empirical approaches may 
operate without knowledge of a drugs molecular target but rely on phenotypic measures. 
This approach benefits from the removal of target bias, taking into account the uncertainty 
of complex multifaceted biological systems.61 The disadvantage, however, are that these 
assays generally require more resources, time and effort as further studies are necessary to 
understand the mechanism(s) of action for lead optimization.59,61,63 
1.3.3 Drug Repurposing and Repositioning 
The progression of drug discovery and development is accompanied by various challenges. 
Some of the major challenges stem from the high cost associated with drug development 
and discovery. Large investments are pumped into drug discovery and development 
projects. Unfortunately, these projects yield low returns owing to the number of drugs that 
make it to the market-a major economic loss.12,42 
 
One attractive approach that is recommended to possibly overcome this obstacle and 
accelerate the drug discovery and development process is the exploration of current drugs 
and drug leads as probable therapies for other diseases. This strategy is known as drug 
repositioning or drug repurposing.42  
 
Drug repurposing refers to a strategy where an existing drug, currently in use in a certain 
disease area, is investigated for use in another disease indication. Drug repositioning, 
however, involves the use of a drug active in one disease indication as a chemical 
modification template to generate derivatives that are employed in another disease area.64 
This strategy can also be applied to rescue drug candidates that have failed or have been 
abandoned during the development process. This shortens the drug discovery process 
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significantly as, in many cases, these drugs have undergone many stages of clinical 
development and, presumably, have known pharmacokinetic and safety profiles.64  
Drug repurposing and repositioning approaches have been used and are currently in use. 
Examples of generic approaches used are exploring: similarities of the drug target and 
genome information; in silico approaches; non-hypothesis driven screening; and as in the 
case of malaria and schistosomiasis similarities in their cell biology. The degradation of 
haemoglobin by the plasmodium parasite and the blood fluke schistosoma suggests an 
opportunity for the repurporsing and repositioning of antimalarial scaffolds/agents as 
antischistosomal agents.42 There are also some successfully 
repurposed/rescued/repositioned drugs that are currently in use such as bupropion, 
repurposed from an antidepressant to smoking cessation; pyrimethamine and other 
antimalarial sulfur-based drugs, which have been repositioned from sulfur-based 
antibacterials. Thalidomide has also been rescued to multiple myeloma64,65 (Figure 12). 
 
Antimalarial chemotherapy has also benefited from drug repurposing. Folate antagonists 
and tetracyclines were initially developed for their impressive antibacterial activity and were 
found to also possess antimalarial activity. These examples suggest the need to screen new 
antimicrobial drugs and other available developed or marketed drugs as potential 
treatments for malaria.16  
 
Figure 12: Successful repurposed/repositioned/rescued drugs 
Previous research work have shown that the reliance of drug discovery eﬀorts in other 
disease areas and the use of these approaches have the potential to improve drug discovery 
in neglected diseases.42 
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1.3.4 Hemoglobin Degradation 
Malarial parasites have limited potential to synthesize their own amino acids. Consequently, 
the parasite degrades hemoglobin of the infected host to liberate amino acids as a source of 
its nutrition.66,67 This is followed by the release of toxic heme, ferriprotoporphyrin IX. Since 
free heme is toxic to the parasite, the parasite polymerizes the heme to insoluble hemozoin 
(non-toxic polymer form of heme) and globin and is then further hydrolyzed to amino acids 
for its nutrition (Figure 13).68 
 
Figure 13: Haemoglobin degradation pathway69 
Chloroquine, mepacrine and pyronaridine shown in Figure 14 are examples of antimalarial 
agents that have been shown to target hemozoin formation. The inhibition of hemozoin 
formation from heme  is an important therapeutic strategy in antimalarial drug 
discovery16,67 and was carried out in this research project.   
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Figure 14: Structures of chloroquine, pyronaridine and mepacrine 
The β-hematin Inhibition Activity (BHIA) assay is used to screen compounds for their 
inhibitory effect against β-hematin (the synthetic equivalent of hemozoin) formation. Novel 
antimalarial β-hematin inhibitors can form strong complexes with heme (toxic to the 
parasite), to prevent the formation of β-hematin. Improvements in high-throughput 
screening methods and a good understanding of the interaction of drugs with this target 
have been essential in drug discovery. This allows for the exploration of heme-targeting 
drug candidates and provides opportunities for target-based structural design for the 
development of novel drugs.68 
 
The discovery that Schistosoma also convert heme to the non-toxic form (hemozoin) 
suggests that new heme-targeting novel drugs are not only essential for malaria but are 
potential chemotherapeutic agents for schistosomiasis.42 
 The Role of Solubility in Drug Discovery 1.4
Solubility is an important factor in drug discovery and needs to be carefully considered in 
order to reduce chances of failure later on in the drug development process.70 Compounds 
with poor solubility profiles result in numerous drawbacks such as poor absorption, hence 
poor bioavailability, inaccurate and unreliable bioassay results arising from compound 
precipitation from solution during the experimental procedure. This, therefore, calls for the 
need to prioritize the optimization of solubility in the early stages of drug discovery. 
Developing drugs with desirable aqueous solubility and permeability, which are the two 
most important physicochemical properties, results in favourable oral bioavailability. 
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Subsequently, the degree of absorption will have an impact on the fraction of the 
administered dose that reaches systemic circulation, hence bioavailability. Therefore, it is 
vital that solubility is optimized in lead molecules.70 
 
In the context of oral drug administration, the drug needs to dissolve in intestinal media 
prior to absorption into systemic circulation. Poor absorption is one of the major reasons 
that prevent many drug candidates from reaching the market. It is therefore economically 
desirable to ensure that sub-optimal solubility profiles of drug candidates are addressed 
during the early development stages.70 
 
The solubility of compounds can be improved using various methods which include physical, 
chemical and supramolecular methods.70 The use of solid dispersions, micronization and the 
selection of polymorphs with optimum solubility are examples of physical methods. The 
micronization method lowers the size of the drug particles, which, in turn, increases its 
surface area to volume ratio thus increasing the dissolution rate. Solid dispersions are 
mixtures of non-polar drugs with hydrophilic carrier polymers that enhance solubility.71  
 
Conversely, supramolecular approaches involve the use of either cyclodextrin inclusion 
complexes or co-crystals. Co-crystal formation between the lipophilic active pharmaceutical 
ingredient (API) and more hydrophilic co-formers enhances both the compound’s solubility 
and oral bioavailability, which is desirable.72 
 
Cyclodextrins can be classified into three main groups: α-, β- or γ, where the number of 
sugars in the cyclic ring determines the category (Figure 15). The cyclic oligosaccharide is 
made up of non-polar interior cavities and polar groups on its exterior. Due to the 
hydrophobic nature of the inner cavities, when in aqueous solution, the interior is occupied 
by water at high enthalpy. This, together with hydrophobic guest molecules, form 
cyclodextrin inclusion complexes.73 
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Figure 15: The structures of alpha (α), beta (β) and gamma (γ) cyclodextrins74 
Chemical methods were explored in this research project and involved the chemical 
modification of a given compound template to improve its aqueous solubility. Approaches 
that are used for chemical modifications in order to improve solubility include introducing 
ionizable groups; introducing polar groups; and using other hydrogen-bonding groups such 
as hydroxyl, amino, amides and carboxylic acids.75 The goal is to reduce both the lipophilicity 
of molecules and improve interactions with aqueous media which can be achieved by 
introducing hydrophilic functional groups (Figure 16 and Figure 17).70  
Solubility affects oral bioavailability which is well illustrated in Figure 16. L-685,434 and 
indinavir are protease inhibitors that have potent activity in vitro in both enzyme and cell-
based assays. However, the early lead compound, L685,434 demonstrated poor in vivo 
efficacy possibly due to poor solubility and therefore low bioavailability. To overcome this 
hurdle, indinavir was optimized from L-685,434 by introducing ionizable centers to improve 
the oral bioavailability of the compound (Figure 16).76 
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Figure 16: Influence of solubility on oral bioavailability76 
Reducing the lipophilicity of a molecule improves its solubility because lowering lipophilicity 
in some cases involves decreasing the size of the molecule. This can be done by first 
identifying lipophilic components in the molecule that can be replaced with smaller or polar 
groups.70,75  
Addition of hydrogen bond donors and acceptors can improve aqueous solubility. Figure 17 
shows nystatin, a poorly soluble but potent antifungal agent. To address this 
pharmacokinetic liability, structural modifications via the addition of hydrogen bonds were 
employed to improve solubility. Introducing hydroxyl groups at positions 31 in compound 
C17.1 and 33 in compound C17.2 displayed a 2000-fold increase in solubility (Figure 17).76 
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Figure 17: Effect of the addition of hydrogen bonding on aqueous solubility76 
Intermolecular interactions involving pi-pi stacking contribute to poor solubility. This is 
because molecules with this type of interaction are capable of forming crystals that require 
high energy to disrupt. However, such molecular interactions can be substantially 
discouraged by incorporating molecular features that disrupt molecular planarity (removal 
of aromaticity or introduction of saturation) and symmetry as well as increase the dihedral 
angle for biaryl systems. Substitution of benzylic positions and twisting of fused rings can 
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also disrupt pi-pi intermolecular interactions. These strategies can discourage crystal 
packing and therefore improve solubility.75,76 Figure 18 illustrates an example of this 
strategy using vanilloid receptor 1 antagonists. 
 
Figure 18: Enhanced solubility via the removal of aromaticity75 
 
Compound C18.1 displayed poor thermodynamic aqueous solubility. In an effort to improve 
this, a second-generation clinical candidate was developed by the removal of aromaticity to 
form the more soluble saturated compound C18.2 (Figure 18). 
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CHAPTER 2: PYRIDO[1,2-a]BENZIMIDAZOLES 
 Introduction 2.1
This chapter covers the design, synthesis, and characterization of the synthesized 
pyrido[1,2-a]benzimidazole (PBI) compounds. Various amine groups were introduced at the 
R6 position of the PBI scaffold (Figure 19) in an attempt to maintain/ improve biological 
activity and enhance aqueous solubility. The modifications on the LHS portion of the PBI at 
positions R1, R2 and R3 were aimed at improving both potency and metabolic stability. 
 
A multistep protocol was employed to synthesize the target compounds using a synthetic 
route reported in literature.1 The synthesized PBI derivatives were further characterized and 
tested for biological activity and their physicochemical properties analyzed. 
 
Figure 19: Generic pyrido[1,2-a]benzimidazole scaffold 
2.1.1 Background 
The chemical structure of benzimidazoles consists of two fused rings: a benzene and an 
imidazole (Figure 20). Benzimidazoles have shown favourable biological properties desirable 
in drug discovery.2,3,4   
Pyrido[1,2-a]benzimidazoles are compounds composed of three fused rings: a pyridine, an 
imidazole and a benzene ring (Figure 20). 
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Figure 20: Chemical structures of benzimidazole and pyrido[1,2-a]benzimidazole. 
 
2.1.2 Pharmacological activity 
The benzimidazole and pyrido[1,2-a]benzimidazole class of molecules have shown a diverse 
range of pharmacological activities, including antifungal,5 antioxidative,6 and 
antiproliferative properties.7  
 
Figure 21: Examples of current drugs with benzimidazoles 
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There are compounds currently available for therapeutic uses that are composed of these 
heterocycylic fused ring systems. On the basis of their bicyclic structure, benzimidazole 
derivatives have been optimized in various disciplines and have led to the generation of 
various pharmacologically active drugs, for example: mebendazole used to treat parasitic 
worm infestations,8,9 droperidol (an antidopaminergic drug), and omeprazole (used to treat 
gastroesophageal reflux) (Figure 21).3,10,11 Methyl 2-benzimidazolecarbamate (carbendazim) 
is a potential anticancer agent; enviroxime possesses enhanced antiviral activity; and 2-
(trifluoromethyl)benzimidazole derivatives have potent anti-protozoal activity. 
Pyrido[1,2-a]benzimidazoles also possess a diverse range of pharmacological properties. 
Figure 22 below shows various biologically active pyrido[1,2-a]benzimidazoles that 
demonstrate antifungal12 and anticancer13 properties. 
 
Figure 22: Pyrido[1,2-a]benzimidazole derivatives as antifungal (1) and anticancer (2), (3), 
(4), (5) agents 
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2.1.3 Antimalarial activity 
In 2000, a library of 1440 diverse non-proprietary compounds underwent in vitro screening 
against protozoa. Through this screen, a pyrido[1,2-a]benzimidazole (PBI) derivative, 
TDR15087 (Figure 23), was identified as moderately active against Plasmodium falciparum 
GHA and W2 strains (IC50 = 0.17 - 0.37 μM). As a result, the various in vitro antiplasmodium 
structure-activity relationships (SARs) of 535 PBI analogues were explored. These 
compounds were evaluated against the chloroquine-resistant Pf strain K1, and cytotoxicity 
was assessed against the mammalian L-6 cell-line. From this screen, over 7% of the 
compounds were identified as active (Pf IC50 < 0.1 µg/mL), including the N-benzylpiperazine 
analogs TDR35885 (Pf K1 IC50 = 0.050 - 0.078 μM) and TDR44047 (Pf K1 IC50 = 0.023 - 0.095 
μM; Figure 23), which displayed both high selectivity and improved in vitro activity 
compared to that of TDR15087 (Pf K1 IC50 = 0.17 - 0.36 μM; Figure 23).
1  
 
Figure 23: Pyrido[1,2-a]benzimidazole screening hits showing in vitro activity against 
Plasmodium falciparum (Pf) 
Despite their in vitro antiplasmodium activity, these piperazinyl-based derivatives (Figure 
23) showed poor in vivo activity in a Plasmodium berghei-infected mouse model at doses up 
to 4 x 100 mg/kg following intraperitoneal (ip) administration, presumably because of their 
low solubility and poor metabolic stability.1 To address these challenges, SAR studies were 
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conducted, resulting in the synthesis of frontrunner PBIs with alkylamino side-chains as 
shown in Figure 24.1 
 
Figure 24: Structure-activity relationship study around the pyrido[1,2-a]benzimidazole core, 
showing potencies (IC50) against the Plasmodium falciparum (Pf) strains NF54 (chloroquine-
sensitive) and K1 (chloroquine-resistant), and the selectivity Index (SI) of lead compounds A 
and B 
Lead compound A displayed sub-micromolar activity against the chloroquine-resistant P. 
falciparum strain K1 (IC50 = 0.047 μM; Figure 24) and negligible cytotoxicity against the 
mammalian cell-line L-6 (SI = 612). Compound B, the mono-desethyl metabolite of A, 
showed in vitro antiplasmodium activity against the chloroquine-sensitive P. falciparum 
strain NF54 (0.12 μM) and the chloroquine-resistant strain K1 (0.11 μM), and a SI of 20.5 
when considering its cytotoxicity against the mammalian cell-line L-6.1  
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After evaluation of the compounds’ in vitro microsomal metabolic stabilities in human, rat, 
and mouse liver microsomes (HLM, RLM, and MLM, respectively), compound A displayed a 
shorter degradation half-life (13.7 min in HLM, 24.8 min in RLM, and 24.1 min in MLM) 
compared to compound B, which exhibited a moderate half-life (136.8 min in HLM, 284.4 
min in RLM, and 321.2 min in MLM).1 
 
Single-dose oral efficacy studies were carried out in a P. berghei-infected mouse model 
using the hydrochloride salts of the most active compounds (Table 2). These compounds 
showed significant potency (Table 2) when administered at a dose of 25 mg/kg (compound 
A caused a 70.33% reduction in parasitemia on day 5) and 50 mg/kg (compound A caused a 
78.22% reduction in parasitemia on day 5). However, antimalarial activity did not improve 
significantly at the higher dose, presumably due to systemic exposure saturation 
attributable to solubility-limited absorption. The orally administered salt of compound B 
was evaluated in single- and multi-dose in vivo efficacy studies in a P. berghei-infected 
mouse model. This revealed that efficacy increased with doses greater than 25 mg/kg. 
Administration of a 50 mg/kg dose caused 50.24%, 71.22%, and 79.79% reductions in 
parasitemia on days 3, 4, and 5, respectively (Table 2). A similar result was observed after 
subcutaneous administration. Preliminary systemic exposure studies following both oral and 
subcutaneous administration of the compound B salt also showed saturation at oral doses > 
25 mg/kg and subcutaneous doses of 50 mg/kg. This replicated observation led to the 
conclusion that solubility-limited absorption resulted in poor bioavailability of the 
compounds, and thus in limited systemic exposure and poor efficacy with increasing 
dosage.1 
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Table 2: Oral efficacy of dihydrochloride salts of selected pyrido[1,2-a]benzimidazole compounds 
in a Plasmodium berghei-infected mouse model 
 
 
 
Compound R 
Dose 
(mg/kg) 
 
% Reduction in parasitemia 
MSD     
(days) 
Day 2 Day 3 Day 4 Day 5 
(A)  1×50 5.15 29.76 59.97 78.22 8 
(A)  1×25 13.07 24.38 51.13 70.33 8 
(B)  1×50 30.78 50.24 71.22 79.79 12.7 
(B)  1×25 23.51 55.45 62.25 68.92 13.3 
1.3 
 
1×50 14.04 47.92 73.01 88.53 8.7 
1.3 
 
1×25 14.75 43.20 63.73 63.72 7.7 
1.4 
 
1×50 23.38 9.30 0.00 0.00 5 
1.4 
 
1×25 28.44 28.07 38.72 46.41 12.7 
Chloroquine  1×10 99.99 - - - 9 
Control  - - - - - 5 
MSD, mean survival days 
 
Further SAR investigations were carried out on the PBI frontrunner compound B (Figure 24) 
to generate other PBI derivatives with enhanced pharmacokinetic (PK) profiles, and to 
explore SARs by evaluating the effect of diverse changes around the scaffold on potency and 
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oral absorption in a mouse model. A summary of the various SAR studies of the PBI chemical 
series is shown in Figure 25.14 
 
Figure 25: Summary of structure-activity relationship studies carried out on lead compound 
B, which showed activity against chloroquine-sensitive (NF54) and chloroquine-resistant 
(K1) Plasmodium falciparum strains 
From this SAR study, compounds with favourable antiplasmodium activity, adequate 
solubility, and high microsomal stability were selected for further in vivo evaluation in a P. 
berghei-infected mouse model. The compounds’ in vitro efficacy against the Pf NF54 strain 
and the in vivo oral efficacy of prioritized PBIs in P. berghei-infected mice are listed in Table 
3. The test compounds were administered orally for 4 successive days at different time 
intervals (4, 24, 48, and 72 h) after infection with P. berghei.14  
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Table 3: Antiplasmodium activity against the chloroquine-sensitive Plasmodium falciparum 
strain NF54 and in vivo oral efficacy of prioritized pyrido[1,2-a]benzimidazoles in Plasmodium 
berghei-infected mice 
 
 
 
Compound 
R1 R2 Pf NF54 
IC50 
(µM) 
Oral 
dose 
(mg/kg) 
% Reduction 
in parasitemia 
(MSD)b 
Cured/ 
infected 
mice 
(B)a 
 
 
0.120 
4 X 50 
4 X 25 
4 X 12.5 
4 X 6 
4 X 3 
96.0 (14) 
96.0 (14) 
81.0 (14) 
38.0 (7) 
0(4) 
0/3 
0/3 
0/3 
0/3 
0/3 
2.1 
 
 
0.380 4 X 50 61.0 (24) 1/3 
2.2 
  
0.140 4 X 50 85.0 (7) 0/3 
2.3 
 
 
0.020 
4 X 50 
4 X 30 
4 X 10 
4 X 3 
98.0 (30) 
99.7 (30) 
99.6 (18) 
99.5 (17) 
3/3 
3/3 
0/3 
0/3 
2.4 
  
0.030 
4 X 50 
4 X 30 
4 X 10 
4 X 3 
98.0 (30) 
99.4 (30) 
99.4 (18) 
99.4 (16) 
3/3 
2/3 
0/3 
0/3 
Chloroquine 0.016 4 X 30 99.9 (24)  0/10 
MSD, mean survival days 
a = HCl salt of compound was used 
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Although compound 2.1 (Pf NF54 IC50 = 0.38 µM) displayed lower in vitro antiplasmodium 
activity than compounds B (Pf NF54 IC50 = 0.12 µM) and 2.2 (Pf NF54 IC50 = 0.14µM), it 
displayed high microsomal stability (89% and 100% remaining in HLM and MLM, 
respectively, after 30 min) and improved in vivo efficacy (one mouse cured after 
administration of 4 x 50 mg/kg doses, Table 3). Compounds 2.3 (Pf NF54 IC50 = 0.02 µM) and 
2.4 (Pf NF54 IC50 = 0.03 µM) showed improvement in in vitro antiplasmodium activity and 
retained microsomal stability (> 80% remaining in HLM and MLM after 30 min) compared to 
lead compound B. In the in vivo efficacy assessment, compounds 2.3 and 2.4 were 
completely curative after administration of 4 x 50 mg/kg doses. However, administration of 
lower dosages (4 x 10 mg/kg and 4 x 3 mg/kg), did not cure the infected mice. Subsequent 
PK studies were pursued for compounds 2.3 and 2.4. The assay was carried out in mice 
receiving oral or intravenous doses of 10 mg/kg and 2.5 mg/kg, respectively. Both 
compounds showed slow rates of absorption (Tmax ≥ 10 h) and elimination (CL < 30 
mL/min/kg). Compounds 2.3 and 2.4 showed similar PK profiles as compound B in P. 
berghei-infected mice. This suggests that the improvement observed in the in vivo activities 
of compounds 2.3 and 2.4 is likely attributable to their improved antiplasmodium potencies 
rather than a result of their improved PK profiles.14 
 
Mechanistic studies were also carried out to investigate the potential of PBIs to inhibit the 
formation of hemozoin (Hz). Results obtained from the β-hematin inhibitory activity (BHIA) 
assay showed that overall, this class of compounds are inhibitors of β-hematin formation 
(IC50 < 100 µM). This suggests that the hemoglobin degradation pathway is a potential 
contributory target of this set of compounds.14  
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Figure 26: Structures of compounds 2.3 and 2.4, which showed potent in vitro activity and 
improved in vivo oral efficacy in a Plasmodium berghei-infected mouse model 
(Pf, Plasmodium falciparum; p.o., per oral) 
The structures of compounds 2.3 and 2.4, which showed improved potency, metabolic 
stability, and significantly better in vivo oral efficacy in a P. berghei-infected mouse model, 
are shown in Figure 26. These compounds also displayed high activity against the P. berghei 
liver and P. falciparum gametocyte stages, making them potential multistage-acting drug 
candidates.14 
2.1.4 Antischistosomal activity 
The in vitro and in vivo antischistosomal efficacies of PBIs explored in a recent study15 are 
listed in Table 4. In this study, several compounds (10 µM) were screened against newly 
transformed schistosomula (NTS; Table 4). Compounds that caused > 70% inhibition of 
worm viability were further evaluated against adult Schistosoma mansoni at the same initial 
concentration of 10 µM. Subsequent studies to determine IC50 values were carried out 
against adult S. mansoni.15  
 
Ten compounds were selected based on their potent in vitro activity against NTS and adult 
S. mansoni, favourable cytotoxicity, and moderate to good metabolic stability, and their in 
vivo efficacies against adult S. mansoni were further evaluated. Of these compounds, 70% 
possessed moderate in vivo activity, showing < 50% reduction in both total and female 
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worm (TW and FW, respectively) burden. In mice treated with 400 mg/kg compound B, no 
reduction in FW or TW burden was observed. However, compounds 3.1 and 3.2 (Table 4) 
showed significant TW and FW reduction, which, although lower than the parasite burden 
reduction caused by treatment with praziquantel,16 is superior to that caused by other 
derivatives reported in the literature.17–20 
Table 4: Percentage reduction and IC50 against adult Schistosoma mansoni, metabolic stability in 
mouse liver microsomes, and total and female worm burden reduction in 49-day-old adult S. 
mansoni-infected mice treated with a single 400 mg/kg oral dose 
 
 
 
Compound R1 R2 
IC50 against 
adult 
Schistosoma 
mansoni 
TWR 
(%) 
FWR 
(%) 
Met. Stab. 
(% 
remaining 
after 30 
min of 
incubation 
in MLMs)  
B 
  
2.41 0.0 0.0 97 ± 8.3 
3.1 
  
2.44 58.7 61.3 69 ± 10.8 
3.2 CF3 
 
0.21 54.9 54.3 97 ± 6.1 
TWR, total worm reduction; FWR, female worm reduction; Met. Stab., metabolic stability; 
MLM, mouse liver microsomes 
 
 
PK analysis was carried out to evaluate the PK profile of compound 3.1 administered orally 
at a dose of 20 mg/kg and intravenously at a dose of 2 mg/kg in mice. The compound 
showed slow and incomplete absorption when administered orally (25% at a dose of 20 
mg/kg), presumably because of low systemic exposure attributable to solubility-limited 
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absorption and a short half-life. Although the compounds in this study showed relatively low 
in vivo antischistosomal potency, significant efficacy was observed in S. mansoni-infected 
mice for compounds 3.1 (TWR = 58.7%, FWR = 61.3%) and 3.2 (TWR = 54.9%, FWR = 54.3%; 
Table 4). This suggests that further evaluation of this series of compounds is needed to 
expand SARs and to produce PBIs with improved in vivo antischistosomal efficacy. The 
structures of compounds 3.1 and 3.2, which showed significant worm burden reduction 
efficacy, are shown in Figure 27. 
 
Figure 27: Structures of pyrido[1,2-a]benzimidazole derivatives and their potencies (IC50) 
against adult Schistosoma mansoni  (Met. stab., metabolic stability; MLM, mouse liver 
microsomes; TWR, total worm reduction; FWR, female worm reduction) 
 Aims and Objectives 2.2
2.2.1 Main Objective 
The main objective of this project was to improve the potency and solubility profiles of 
antimalarial and antischistosomal piperazine-based pyrido[1,2-a]benzimidazoles. 
2.2.2 Research Question/ Hypothesis 
Is it possible to identify potential pyrido [1,2-a] benzimidazole-based antimalarial and 
antischistosomal drug leads with favourable solubility, cytotoxicity and in vitro potency? 
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2.2.3 Specific Aims 
i) Synthesis and characterization of piperazine-based pyrido[1,2-a]benzimidazoles 
designed to improve pharmacological activity and/or solubility.  
ii) Profiling of synthesized compounds with respect to antiplasmodium and 
antischistosomal activities as well as solubility. 
iii) Derivation of antiplasmodium and antischistosomal structure-activity 
relationship (SAR) as well as solubility structure property relationship (SPR) 
profiles. 
iv) Investigation of the factors (e.g. melting point, CLogP, and retention time on 
reversed-phase HPLC) affecting solubility and deduce relationships. 
 Rationale 2.3
This project aims to expand the SAR around the N-benzylpiperazine hit, TDR44047 (Figure 
23) by executing medicinal chemistry modifications on the PBI core (Figure 28) with the aim 
of improving biological activity, solubility and metabolic stability. 
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Figure 28:  Chemistry SAR Plan for the synthesis of new piperazine-based pyrido[1,2-
a]benzimidazole derivatives with four regions of diversity, incorporating various solubility 
enhancement strategies 
In SAR I, aryl- and carboxamide-linked analogues as well as analogues containing saturated 
ring systems, were designed. SAR II was guided by the Craig Plot illustrated in Figure 29 
below. Craig plot X substituents were chosen from the various quadrants in order to 
synthesize target molecules with diverse lipophilic and electronic substituents. This SAR also 
included the exploration of various linkers: analogues were either directly linked, 
methylene-linked or ethylene linked to the piperazine moiety attached to the PBI core. 
Regioisomerism was also examined in SAR II, where positional isomers were synthesized, i.e. 
compounds with the same Craig plot X substituent at ortho, meta, and para positions 
(Figure 28). SAR III investigates the effect of introducing a carbonyl moiety on the piperazine 
ring to lower the lipophilicity of the compound and thereby potentially improve its solubility 
profile. SAR IV focuses on potentially improving the potency and metabolic stability of the 
generated compounds based on prior work already mentioned. 
49 
 
 
Figure 29: Craig plot substituents 
The screening cascade summarizes the project work flow followed and the criterion 
required for progression through the flow chart (Figure 30). The work flow began with the 
synthesis and characterization of various PBI derivatives which were then subjected to in 
vitro antiplasmodium and antischistosomal testing. This exercise was conducted in parallel 
with solubility profiling, β-hematin inhibition activity, and gametocyte stage assays. 
Analogues that met the micromolar criterion in the in vitro antiplasmodium and 
antischistosomal activity assays were further evaluated for cytotoxicity against the 
mammalian Chinese Hamster Ovarian (CHO) cell line, aiming for a selectivity index (SI) of at 
least 10. Although not done in the context of this thesis work, compounds with an 
acceptable cytotoxicity profile would be assessed for in vitro metabolic stability. Analogues 
regarded as metabolically stable (i.e. 75% of its parent compound present after 30 minutes), 
would be further prioritized for in vivo pharmacokinetics (PK) to establish primary PK 
parameters such as bioavailability (F) and half-life (T1/2) for the ultimate in vivo efficacy 
studies in a mouse model. Alternatively, in vivo efficacy studies on the in vitro metabolically 
stable compounds would be performed followed by in vivo PK (Figure 30).  
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Figure 30: Screening cascade outlining the research programme from synthesis to in vitro 
cytotoxicity profiling 
 Synthesis and Characterization  2.4
2.4.1 Introduction 
Structural modifications have been employed to explore structure-activity and structure-
property relationships in order to furnish PBI analogues with potentially improved solubility, 
antiplasmodium and antischistosomal potencies.  
 
The synthetic methodology that was employed by Ndakala et al., was adopted to afford the 
various synthesized compounds (Schemes 1 & 5). Scheme 1 shows the steps followed in the 
synthesis of the LHS-unsubstituted PBI target compounds, whereas Scheme 5 depicts the 
approach followed to synthesize LHS-substituted PBI analogues. The latter includes an 
additional step, step (i), a cyclocondensation reaction using a commercially available 
appropriately substituted diaminobenzene with ethyl 2-cyanoacetate to afford intermediate I. 
The subsequent steps (ii) to (iv), however, are common in both schemes (Schemes 1 & 5).   
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The second step (ii) involves a cyclocondensation reaction using the appropriate 
benzimidazole acetonitrile I and reacting it with a β-ketoester in the presence of ammonium 
acetate to afford a tricyclic hydroxyl intermediate II. This intermediate is then subsequently 
chlorinated using phosphoryl chloride via a nucleophilic aromatic substitution reaction in 
the third step (iii). The fourth step (iv) involves amination of the chloro-intermediate using 
various amines via a nucleophilic aromatic substitution reaction in the presence of 
triethylamine to afford the PBI target derivatives in moderate to good yields.  
2.4.2 Syntheses of left hand side-unsubstituted derivatives 
The left hand side-substituted derivatives were synthesized via the scheme shown below 
(Scheme 1). 
 
Scheme 1: Synthetic protocol towards LHS-unsubstituted PBI target compounds. Reagents 
and conditions: (ii) NH4OAc, 140-150 °C, 10h; (iii) POCl3, 130 °C, 8h; (iv) Appropriate amine, 
Et3N, THF, 55-80 °C, 20-60 mins (microwave) 
2.4.2.1 Mechanism for the formation of the cyclized hydroxyl intermediate II 
(Scheme 1&5, step (ii)) 
The second step (ii) involves a cyclisation condensation reaction between the appropriate 
benzimidazole acetonitrile and ethyl 4,4,4-trifluoro-3-oxobutanoate in the presence of 
ammonium acetate to afford a tricyclic hydroxyl intermediate (Scheme 2).  
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Scheme 2: Proposed reaction mechanism for the cyclisation step to form the tricyclic 
hydroxyl intermediate (II) 
In this proposed mechanism, ammonium acetate abstracts the α–proton from 2-
benzimidazole acetonitrile (Step h) to form the imine intermediate (i). This allows a 
nucleophilic attack of the more electrophilic carbonyl group (attached to the trifluoromethyl 
group) of the β-ketoester (Step i). This is followed by proton abstraction from ammonium 
ion leading to the release of ammonia (Step j). The hydroxyl oxygen abstracts the H-OAc 
proton (Step k), to form (l). Subsequently, the carbon-proton bond branching from the 
carbon-acetonitrile carbon forms a double bond (initiated via proton abstraction by the 
II 
I 
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acetate), resulting in the elimination of water (Step l). In the process of aromatization, the 
second electrophilic carbonyl group (attached to the alkoxyl group) is attacked by the 
nucleophilic nitrogen (Step m) to furnish intermediate (n). The amino proton is abstracted 
by the negatively charged oxygen (Step n) to afford intermediate (o). The eliminated alkoxyl 
group then abstracts the proton adjacent to the CF3 group (Step p), and in the process, 
ethanol is lost to give the appropriately substituted tricyclic hydroxyl product (II).  
2.4.2.2 Mechanism for the formation of the chloro intermediate III (Schemes 1&5, 
step (iii)) 
The third step (iii) involves the chlorination of the tricyclic hydroxyl intermediate via 
nucleophilic aromatic substitution using phosphoryl chloride (POCl3) (Scheme 3). 
 
Scheme 3: Proposed reaction mechanism for the cyclisation step to form the tricyclic 
chlorinated intermediate (III) 
The nucleophilic hydroxyl group attacks the electrophilic phosphorus centre, shifting 
electrons to the oxygen of the POCl3 (Step r) to form intermediate (s). The reformation of 
the phosphorous oxygen double bond via rearrangement (Step s) leads to the loss of the 
chloride anion, giving intermediate (t). This intermediate undergoes a substitution reaction 
in which the nucleophilic chloride anion substitutes the phosphorus moiety, resulting in the 
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formation of POCl2 and HCl to leave as side products (Step t) and further furnish the tricyclic 
choro-intermediate (III). 
2.4.2.3 Mechanism for the formation of the aminated target molecule IV (Schemes 
1&5, step (iv)) 
The penultimate step (iv) involves the amination of the chloro-intermediate using 
piperazine in the presence of triethylamine via nucleophilic aromatic substitution to yield 
the PBI target molecules (Scheme 4). 
 
Scheme 4: Proposed reaction mechanism for the amination step to form target molecule 
(IV) 
The formation of the target PBI molecules involves aromatic nucleophilic substitution of the 
chloro intermediate using various amines (Step u). This results in the rearrangement of 
bonds, making the cyano negatively charged, resulting in intermediate (v). The nucleophilic 
cyano group initiates another rearrangement which in turn leads to the loss of a chloride ion 
(Step v). The triethylamine base abstracts the proton on the amine to mop up the acid 
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produced (Step w) in the form of a salt Et3NHCl. This yields the aminated PBI target 
molecule (IV) and Et3NHCl as a by-product. 
2.4.3 Syntheses of left hand side-substituted derivatives 
Left Hand Side-substituted derivatives were synthesized via the scheme shown below 
(Scheme 5). 
 
Scheme 5: Synthetic protocol towards LHS-substituted PBI target compounds. Reagents and 
conditions: (i) DMF, 160 °C, 9-12h; (ii) NH4OAc, 140-150 °C, 10h; (iii) POCl3, 130 °C, 8h; (iv) 
Appropriate amine, Et3N, THF, 55-80 °C, 20-60 mins (microwave) 
2.4.3.1 Mechanism for the formation of the intermediate I (Scheme 5, step (i)) 
The first step (i) involves a cyclisation reaction that forms a benzimidazole acetonitrile 
(Scheme 6). 
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Scheme 6: Proposed reaction mechanism for the first cyclisation step to form intermediate 
(I) 
The appropriate diaminobenzene reacts with ethyl cyanoacetate. The first step is initiated 
by nucleophilic attack of the electrophilic carbonyl carbon by one of the amino groups 
attached to the diaminobenzene, resulting in the loss of the ethoxyl group (Step a) to form 
intermediate (b). Abstraction of an amino proton by the eliminated ethoxyl group (Step b) 
results in attack of the electrophilic carbonyl centre by the nucleophilic lone pairs of the 
other amino group bonded to the diaminobenzene (Step c) to give intermediate (c). This 
leads to the initial formation of the second ring (d) which, via proton transfer, results in a 
cyclized carbinolamine intermediate (e). The double bond formed by the lone pair of 
electrons from the amino group leads to the loss of a hydroxide ion giving intermediate (f). 
57 
 
Finally, the loss of water via the abstraction of a proton by the hydroxide ion (Step f) 
furnishes the appropriately substituted benzimidazole acetonitrile (I).        
 Spectroscopic Analysis of Key Intermediates and Final Target 2.5
Compounds. 
2.5.1 Benzimidazole acetonitrile intermediate I 
The characteristic 1H NMR spectrum of intermediate I (Scheme 2) is shown in Figure 31. 
 
 
Figure 31: 1H NMR spectrum of intermediate I in DMSO-d6 at 300 MHz 
The diagnostic broad singlet at δ 13.17 ppm, integrating for one proton, corresponds to the 
NH proton H-3. Another characteristic feature of compound I on the spectrum is the 
appearance of a singlet at δ 4.43 ppm, which integrated for two protons, and was assigned 
to the two H-4 hydrogens. The signals due to protons H-2 and H-1 yielded two resolved 
doublets at δ 7.63 ppm and δ 7.39 ppm both with a small coupling constant (J = 1.7 Hz) due 
to a long-range coupling with proton H-1 and H-2 respectively. 
H-3 (s)          
13.17                    
 
H-2 (d)          
7.63 
J = 1.8                    
 
H-1 (d)          
7.39 
J = 1.8                    
 
H-4 (s)          
4.43                    
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2.5.2 Hydroxyl intermediate II 
The 1H NMR spectrum of intermediate II (Scheme 1) is shown in Figure 32 below. 
 
Figure 32: 1H NMR spectrum of intermediate II in DMSO-d6 at 400 MHz 
The doublet of doublets observed in the aromatic region at δ 8.59 ppm can be allocated to 
proton H-1, as a result of the short-range coupling to H-2 (J = 8.2 Hz), and the long-range 
coupling to H-3 (J = 1.1 Hz). The signal at δ 7.63 ppm, integrating for one proton (H-4) 
appears as a doublet of doublets due to the adjacent short-range hydrogen H-3 (J = 8.3 Hz), 
and the long-range H-2 (J = 1.0 Hz) proton. The doublet of doublet of doublets at δ 7.61 ppm 
(H-3) appears as a result of the short-range protons H-4 (J = 8.2 Hz), H-2 (J = 7.2 Hz), and the 
long-range H-1 (J = 1.1 Hz) proton. The signal at δ 7.45 ppm, integrating for one proton is 
associated with the aromatic proton H-2, and appears as a doublet of doublet of doublets 
due to the short-range hydrogens H-1 (J = 8.3 Hz) and H3 (J = 7.1 Hz), and the long-range H4 
(J = 1.2 Hz) proton. The sharp singlet, integrating for one proton at δ 6.41 ppm corresponds 
to proton H5 which has no neighboring protons. 
2.5.3 Chloro intermediate III 
The 1H NMR spectrum of intermediate III (Scheme 1) is shown in Figure 33 below. 
H-1 (dd)      
8.59                   
J = 8.2, 1.1 
  
H-4 (dd)      
7.63                   
J = 8.3, 1.0 
 
  H-3 (ddd)      
7.61                      
J = 8.2, 7.2, 1.1 
 
  H-2 (ddd)      
7.45                      
J = 8.3, 7.1, 1.2 
 
H-5 (s)      
6.41                    
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Figure 33: 1H NMR spectrum of intermediate III in DMSO-d6 at 600 MHz. 
The 1H-NMR spectrum of intermediate III (Figure 33) is characterized by the presence of a 
singlet at δ 7.79 ppm due to H-5, also present in the hydroxyl intermediate II (Figure 32). 
This singlet appears at a higher chemical shift compared to that of intermediate II (Figure 
32), as a result of the deshielding effect of the chloro substituent. The two doublet of 
doublets, H-1 and H-4 each have one neigbouring hydrogen H-2 (J = 8.2 Hz) and H-3 (J = 8.2 
Hz), a long-range coupling to H-3 (J = 1.0 Hz) and H-2 (J = 1.1 Hz) respectively, and both 
integrate for one proton. The signal corresponding to H-3 yielded a doublet of doublet of 
doublets resonating at δ 7.81 ppm with a small coupling constant due to a long-range 
coupling with proton H-1 (J = 1.0 Hz), and two large coupling constants due to the adjacent 
protons H-4 (J = 8.2 Hz), and H-2 (J = 7.2 Hz). The doublet of doublet of doublets in the 
aromatic region at δ 7.63 ppm (H-2) appears as a result of the short-range protons H-1 (J = 
8.1 Hz), H-3 (J = 7.1 Hz) and the long-range H-4 (J = 1.1 Hz) proton.  
2.5.4 Aminated compound IV 
The 1H NMR and 13C NMR spectra of intermediate IV (Scheme 1) are shown in Figure 34 and 
Figure 35 respectively.  
 
H-1 (dd)      
8.78                   
J = 8.2, 1.0 
 
H-4 (dd)      
8.11                   
J = 8.2, 1.1 
 
 
H-3 (ddd)      
7.81                       
J = 8.2, 7.2, 1.0 
 
H-5 (s)             
7.79 
 
H-2 (ddd)      
7.63                      
J = 8.1, 7.1, 1.1 
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The two doublets of doublets, arising from two hydrogens at δ 8.44 ppm and 8.01 ppm are 
attributed to the aromatic hydrogens, H-1 and H-4. Another characteristic peak of target 
compound IV is the doublet of doublet of doublets (H-3), at δ 7.70 ppm, sandwiched 
between two neighbouring protons H-4 (J = 8.3 Hz), H-2 (J = 7.2 Hz), and the long-range 
proton H-1 (J = 1.0 Hz). The doublet integrating for two protons (H-8; J = 8.1 Hz) at δ 7.21 
ppm is owing to the adjacent H-9 hydrogens. The sharp singlet that appears on the spectra 
is as a result of proton H-5, and is a common signal in all intermediates, appearing at δ 6.92 
ppm attributable to the absence of neighbouring hydrogens. The multiplets correspond to 
the aromatic protons (H-2, H-9; δ 7.6 - 7.5 ppm) and piperazinyl hydrogens (H-6, H-7; δ 3.1-
3.0 ppm), integrating for three protons and eight hydrogens respectively. 
13C NMR spectroscopy contributed to the confirmation of the chemical structures of the 
synthesized intermediates and final target compounds.  
 
H-1 (dd)      
8.44                   
J = 8.3, 1.0 
 
H-4 (dd)      
8.01                   
J = 8.3, 1.0 
 
H-3 (ddd)               
7.70                        
J = 8.3, 7.2, 1.0 
 
H-2, H-9 (m)          
7.57                    
 
H-8 (d)          
7.21                   
J = 8.1 
 
H-5 (s)          
6.92                    
 
H-6, H-7 (m)        
3.08                    
 
DMSO-d6 
 
H2O from 
DMSO-d6 
 
 
Figure 34: 1H NMR spectrum of intermediate IV in DMSO-d6 at 400 MHz. 
61 
 
 
Figure 35: 13C NMR spectrum of target compound IV in DMSO-d6 at 101 MHz 
The carbons labelled in Figure 35 are some of the common signals that were found in target 
compounds. C-13 is the most downfield-resonating carbon (δ 154.0) because of the 
neighbouring nitrogen atoms that cause considerable deshielding, giving rise to a high 
chemical shift value. In contrast, signals due to the piperazinyl carbons, appeared upfield on 
the spectrum with relatively high intensities due to each signal occupying two chemical 
shift-equivalent carbons C-15 (δ 46.8) and C-14 (δ 46.2). In addition, the similar electronic 
environments of aromatic carbons C-3 and C-4 resulted in a downfield signal, appearing at 
the same chemical shift (δ 120.1). The carbon on the pyridine ring of the pyrido[1,2-
a]benzimidazole scaffold with a cyano group attached to it is another common signal in the 
targets and was assigned to carbon C-9 (δ 96.8). 
 
The isolated yields obtained at the different synthetic steps are indicated in schemes 1 & 5 
above. The procedures at the different reaction steps were optimized to yield target 
compounds with moderate to good yields (Table 5).  
C-15 x 2 
C-14 x 2 
C-13 
C-9 
DMSO-d6 
C-3, C-4 
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Table 5: Isolated percentage yields for PBI target compounds. 
 
 
 
Compound X Y Z R1 R2 Yield (%) 
1 
(CN1-034) 
H H H 
 
CF3 86 
2 
(CN1-035) 
H H H 
 
CF3 81 
3 
(CN1-036) 
H H H 
 
CF3 83 
4 
(CN1-037) 
H H H 
 
CF3 83 
5 
(CN1-038) 
H H H 
 
CF3 83 
6 
(CN1-040) 
H H H 
 
CF3 90 
7 
(CN1-041) 
H H H 
 
CF3 67 
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Compound X Y Z R1 R2 Yield (%) 
8 
(CN1-042) 
H H H 
 
CF3 86 
9 
(CN1-043) 
H H H 
 
CF3 75 
10 
(CN1-044) 
H H H 
 
CF3 67 
11 
(CN1-045) 
H H H 
 
 
CF3 91 
12 
(CN1-048) 
H H H 
 
CF3 93 
13 
(CN1-049) 
H H H 
 
CF3 90 
14 
(CN1-050) 
H H H 
 
CF3 87 
15 
(CN1-051)a 
H H H 
 
 
88 
64 
 
 
 
Compound X Y Z R1 R2 Yield (%) 
16 
(CN1-052) 
H H H 
 
CF3 80 
17 
(CN1-059) 
H Cl Cl 
 
CF3 66 
18 
(CN1-060) 
H Cl Cl 
 
CF3 82 
19 
(CN1-061) 
H Cl Cl 
 
CF3 72 
20 
(CN1-062) 
H Cl Cl 
 
CF3 89 
21 
(CN1-063) 
H H H 
 
CF3 70 
22 
(CN1-064) 
H H H 
 
CF3 88 
23 
(CN1-065) 
H H H 
 
CF3 91 
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Compound X Y Z R1 R2 Yield (%) 
24 
(CN1-066) 
H H H 
 
CF3 90 
25 
(CN1-067) 
H H H 
 
CF3 63 
26 
(CN1-068) 
H H H 
 
CF3 63 
27 
(CN1-069) 
H H H 
 
CF3 77 
28 
(CN1-070) 
H H H 
 
CF3 65 
29 
(CN1-071) 
H H H 
 
CF3 84 
30 
(CN1-072) 
H H H 
 
CF3 67 
31 
(CN1-077) 
Cl H Cl 
 
CF3 91 
66 
 
 
 
Compound X Y Z R1 R2 Yield (%) 
32 
(CN1-078) 
Cl H Cl 
 
CF3 76 
33 
(CN1-079) 
H F F 
 
CF3 74 
34 
(CN1-080) 
H F F 
 
CF3 73 
35 
(CN1-082) 
H H H 
 
CF3 90 
36 
(CN1-083) 
H H H 
 
CF3 73 
a, lead compound (TDR44047) 
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CHAPTER 3: PHARMACOLOGICAL EVALUATION 
 Introduction 3.1
The in vitro antiplasmodium activities of the final synthesized target compounds were 
evaluated against the blood-stage parasites of the chloroquine-sensitive P. falciparum NF54 
strain (Table 6). Concurrently, antischistosomal activities against Newly Transformed 
Schistosomula (NTS) and adult S. mansoni were evaluated (Table 8). Pyrido[1,2-
a]benzimidazole (PBI) derivatives were also screened for in vitro gametocytocidal activity 
using the luciferase-reporter NF54 line of P. falciparum and tested at a concentration of 1 
and 5 µM (Table 7). 
 
This research project also included a mechanistic study that explored the potential of 
piperazinyl PBIs to inhibit the formation of hemozoin (Hz) based on the hypothesis that the 
PBI scaffold can potentially adopt flat conformations that would encourage π−π stacking 
interactions with ferriprotoporphyrin IX (Fe(III)PPIX), the toxic by-product of host 
hemoglobin degradation. This interaction would inhibit Hz formation, leading to the death 
of the parasite via heme toxicity.  
 In vitro antiplasmodium (Pf NF54) and β-hematin inhibitory 3.2
activities 
One of the most active compounds in this PBI series was compound 10 (IC50 = 0.09 µM), 
which contains a piperazine ring and a cyclohexane saturated substituent. The saturated R1 
group confers approximately 39 times more potency than the unsaturated R1 amine group 
in compound 21 (IC50 = 3.52 µM). However, the addition of the NMe group to the saturated 
cyclohexane part of the R1 group in analogue 30 (IC50 > 6.00 μM) presumably interfered with 
the essential interactions required for potency. 
 
The presence of either a methylene linker, in compound 2 (IC50 = 0.31 µM), or an ethylene 
linker, in compound 6 (IC50 = 0.33 µM), at the R1 position resulted in significant activity, 
indicating the importance of these linkers for potency. The analogue containing a methylene 
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linker, PBI benzyl derivative 1 (IC50 = 0.17 µM), showed approximately a 3-fold increase in 
activity compared to the linker-free fluorobenzyl piperazine analogue 4 (IC50 = 0.43 µM). 
Although the directly linked phenyl piperazine compound 21 (IC50 = 3.52 µM) showed poor 
antiparasitic activity, the introduction of fluoro (compound 4, IC50 = 0.43 µM), chloro 
(compound 27, IC50 = 0.68 µM), and trifluoromethyl (compound 9, IC50 = 0.91 µM) Craig plot 
substituents at the para position of the benzyl group enhanced antiplasmodium activity.  
 
Introduction of a carbonyl group to the methylene linker resulted in the loss of 
antiplasmodium activity (compound 5, IC50 = 6.00 μM).  
 
Addition of the hydrophobic electron-withdrawing fluoro, chloro, and trifluoromethyl 
substituents favored antiplasmodium activity (compound 4, IC50 = 0.43 μM; compound 9, 
IC50 = 0.91 μM; and compound 27, IC50 = 0.68 µM), compared to the hydrophobic electron-
releasing methyl group (compound 7, IC50 = 1.29 μM) and the hydrophilic electron-
withdrawing cyano group (compound 8, IC50 = 4.20 μM). 
 
In the LHS-unsubstituted series of compounds, regio-isomerism on the benzyl moiety 
attached to the piperazine at R1 showed no influence on activity: compounds 1 (IC50 = 0.17 
μM), 12 (IC50 = 0.14 μM), and 13 (IC50 = 0.10 μM) displayed equipotent antiplasmodium 
activity. This observation was consistent with that seen in LHS-substituted compounds 18 
(IC50 = 1.77 μM), 19 (IC50 = 1.58 μM), and 20 (IC50 = 1.96 μM), in which positional isomers 
demonstrated comparable antiplasmodium activity. 
 
LHS-substituted analogues were synthesized to investigate the effect of di-substitution on in 
vitro antiplasmodium activity and BHIA. Dichloro- and difluoro-substituted analogues of the 
potent parent unsubstituted compounds were accordingly synthesized. The di-substituted 
compounds were synthesized with either the 1-(4-fluorobenzyl)piperazine, employed in 
analogue 1, or the 1-cyclohexylpiperazine amine used to synthesize compound 10. These 
amino side-chains were prioritized based on the high antiplasmodium activity they 
conferred to the LHS-unsubstituted analogues compounds 1 (IC50 = 0.17 μM) and 10 (IC50 = 
0.09 µM). 
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The LHS-substituted 3,5 di-chlorinated analogues 31 (IC50 = 0.18 µM) and 32 (IC50 = 1.71 
µM), and the 4,5 di-chlorinated analogues 17 (IC50 = 0.11 µM) and 18 (IC50 = 1.77 µM) 
displayed comparable activity but reduced antiplasmodium potency compared to that of 
their parent unsubstituted analogues (compounds 10, IC50 = 0.09 µM, and 1, IC50 = 0.17 μM). 
The LHS-substituted di-fluorinated analogues, however, displayed markedly enhanced 
antiplasmodium activity (compounds 33, IC50 = 0.012 µM, and 34, IC50 = 0.10 µM).  
Table 6: In vitro activity against the chloroquine-sensitive Plasmodium falciparum (Pf) NF54 strain 
and inhibition of β-hematin formation by pyrido[1,2-a]benzimidazoles 
 
Compound X Y Z R1 R2 
Antiplasmodium 
activity 
IC50 (µM) 
IC50 
BHIA 
(µM) 
Pf NF54  
1 
(CN1-034) 
H H H 
 
CF3 0.17 580 
2 
(CN1-035) 
H H H 
 
CF3 0.31 689 
3 
(CN1-036) 
H H H 
 
CF3 4.60 85000 
4 
(CN1-037) 
H H H 
 
CF3 0.43 606985 
5 
(CN1-038) 
H H H 
 
CF3 6.00 n.a. 
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Compound X Y Z R1 R2 
Antiplasmodium 
activity 
IC50 (µM) 
IC50 
BHIA 
(µM) 
Pf NF54  
6 
(CN1-040) 
H H H 
 
CF3 0.33 1011 
7 
(CN1-041) 
H H H 
 
CF3 1.29 n.a. 
8 
(CN1-042) 
H H H 
 
CF3 4.20 1380 
9 
(CN1-043) 
H H H 
 
CF3 0.91 685 
10 
(CN1-044) 
H H H 
 
CF3 0.09 20 
11 
(CN1-045) 
H H H 
 
CF3 5.46 n.a. 
12 
(CN1-048) 
H H H 
 
CF3 0.14 17 
13 
(CN1-049) 
H H H 
 
CF3 0.10 239 
14 
(CN1-050) 
H H H 
 
CF3 1.11 3681 
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Compound X Y Z R1 R2 
Antiplasmodium 
activity 
IC50 (µM) 
IC50 
BHIA 
(µM) 
Pf NF54  
15 
(CN1-051)a 
H H H 
 
 
 
0.040 n.a. 
16 
(CN1-052) 
H H H 
 
 
       
CF3 2.62 n.a. 
17 
(CN1-059) 
H Cl Cl 
 
CF3 0.11 288 
18 
(CN1-060) 
H Cl Cl 
 
CF3 1.77 379 
19 
(CN1-061) 
H Cl Cl 
 
CF3 1.58 513 
20 
(CN1-062) 
H Cl Cl 
 
CF3 1.96 122 
21 
(CN1-063) 
H H H 
 
CF3 3.52 n.a. 
22 
(CN1-064) 
H H H 
 
CF3 3.58 1120 
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Compound X Y Z R1 R2 
Antiplasmodium 
activity 
IC50 (µM) 
IC50 
BHIA 
(µM) 
Pf NF54  
23 
(CN1-065) 
H H H 
 
CF3 1.83 30630 
24 
(CN1-066) 
H H H 
 
CF3 3.84 n.a. 
25 
(CN1-067) 
H H H 
 
CF3 2.36 340840 
26 
(CN1-068) 
H H H 
 
CF3 > 6.00 n.a. 
27 
(CN1-069) 
H H H 
 
CF3 0.68 895 
28 
(CN1-070) 
H H H 
 
CF3 0.62 48516 
29 
(CN1-071) 
H H H 
 
CF3 1.45 6284 
30 
(CN1-072) 
H H H 
 
CF3 > 6.00 29876 
31 
(CN1-077) 
Cl H Cl 
 
CF3 0.18 420 
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Compound X Y Z R1 R2 
Antiplasmodium 
activity 
IC50 (µM) 
IC50 
BHIA 
(µM) 
Pf NF54  
32 
(CN1-078) 
Cl H Cl 
 
CF3 1.71 255 
33 
(CN1-079) 
H F F 
 
CF3 0.012 138 
34 
(CN1-080) 
H F F 
 
CF3 0.10 689 
35 
(CN1-082) 
H H H 
 
CF3 1.78 2482 
36 
(CN1-083) 
H H H 
 
CF3 2.54 19836 
Chloroquine   0.014 
 
17 
 
Amodiaquine   0.009 15 
Pyrimethamine   0.019 1018 
a, lead compound (TDR44047) 
BHIA, β-hematin inhibitory activity; n.a., not assessed 
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Generally, compounds that displayed potent BHIA also showed high antiplasmodium 
activity, as observed with compounds 10 (BHIA IC50 20 μM, NF54 IC50 0.09 μM), 12 (BHIA IC50 
17 μM, NF54 IC50 0.14 μM), and 33 (BHIA IC50 138 μM, NF54 IC50 0.012 μM). Despite this 
observation, the linear correlation between the Pf NF54 whole-cell and the BHIA assays, 
although statistically significant, was weak. A graph plotting log IC50 and log BHIA for the 20 
most potent compounds (NF54 IC50 < 2 μM) illustrates this trend (Figure 37). Although the 
plot shows a general trend, the relationship between the two properties cannot be 
concluded from the graph. The low R2 value of the graph in Figure 37 (R2 = 0.1641) is an 
indication of the lack of correlation between these two properties, and suggests that β-
hematin inhibition maybe potentially a contributing mode of action, rather than the sole 
mechanism of antiplasmodial activity for this class of compounds. However, it is important 
to note that the BHIA assay is a cell-free assay and therefore does not represent the true 
environment of the food vacuole. Furthermore, the BHIA assay is carried out in the absence 
of membranes, although in vivo, the drug would have to cross multiple membrane barriers 
to permeate the infected red blood cells and the parasite to reach its target in the digestive 
food vacuole. The compound’s physicochemical properties are thus important to consider in 
predicting its ability to cross membranes. A cellular fractionation assay is therefore required 
to address the assay’s shortcomings and further validate these results. In the cell 
fractionation assay, free heme and Hz are measured in ring-stage parasites treated with 
increasing doses of compound. A true β-hematin formation inhibitor displays a dose-
dependent increase in toxic free heme and a decrease in Hz. 
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Figure 36: Correlation between antiplasmodium and β-hematin inhibitory activity of the PBI 
compounds 
 Gametocytocidal Activity 3.3
Compounds that display gametocytocidal activity are of interest with regard to malaria 
because of their transmission-blocking potential. The ability of this class of compounds to 
act as dual-action antimalarials was evaluated by screening compounds against luciferase 
reporter-expressing P. falciparum NF54 parasites. The percentage inhibition of each 
compound tested (1 μM and 5 μM) against early- and late-stage P. falciparum gametocytes 
(EGs and LGs, respectively) is shown in Table 7.  
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Table 7: In vitro gametocytocidal activity of compounds (1 μM and 5 μM) on early- and late-stage 
Plasmodium falciparum gametocytes  
 
 
Compound 
 
Y Z R1 R2 
EG LG 
1 µM 
(%) 
5 µM 
(%) 
1 µM 
(%) 
5 µM 
(%) 
1 
(CN1-034) 
H H 
 
CF3 19 15 3 5 
2 
(CN1-035) 
H H 
 
CF3 17 15 2 14 
4 
(CN1-037) 
H H 
 
CF3 15 7 11 4 
6 
(CN1-040) 
H H 
 
CF3 22 20 20 28 
7 
(CN1-041) 
H H 
 
CF3 1 9 4 2 
9 
(CN1-043) 
H H 
 
CF3 4 1 28 15 
10 
(CN1-044) 
H H 
 
CF3 32 28 26 0 
12 
(CN1-048) 
H H 
 
CF3 23 23 12 15 
13 
(CN1-049) 
H H 
 
CF3 8 37 24 24 
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Compound 
 
Y Z R1 R2 
EG LG 
1 µM 
(%) 
5 µM 
(%) 
1 µM 
(%) 
5 µM 
(%) 
14 
(CN1-050) 
H H 
 
CF3 0 0 8 9 
15 
(CN1-051)a 
H H 
 
 
 
14 34 28 22 
17 
(CN1-059) 
Cl Cl 
 
CF3 3 29 0 19 
23 
(CN1-065) 
H H 
 
CF3 2 3 1 3 
25 
(CN1-067) 
H H 
 
CF3 1 2 1 8 
27 
(CN1-069) 
H H 
 
CF3 2 2 27 34 
28 
(CN1-070) 
H H 
 
CF3 13 18 32 36 
29 
(CN1-071) 
H H 
 
CF3 0 0 4 7 
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Compounds that were tested for gametocytocidal activity showed minimal activity against 
both EGs and LGs (< 50% inhibition at both 5 μM and 1 μM).  
 
 
 
Compound 
 
Y Z R1 R2 EG LG 
1 µM 
(%) 
5 µM 
(%) 
1 µM 
(%) 
5 µM 
(%) 
36 
(CN1-083) 
H H 
 
 
CF3 1 7 2 7 
Methylene blue     93  90  
Dihydro-
artemisinin 
    75  70  
MMV390048     77  92  
a, lead compound (TDR44047) 
EG, early-stage gametocytes; LG, late-stage gametocytes 
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 In vitro antischistosomal activities   3.4
Twenty-three target compounds were screened against NTS and adult S. mansoni at an 
initial concentration of 10 μM (Table 8). In the case of NTS, compounds 4, 9, and 24 
displayed potent activity against the juvenile parasite (>70% inhibition of worm viability). 
The compounds that met this threshold were selected for subsequent evaluation against 
adult S. mansoni. 
Compounds 4 and 24 maintained their potency at the same drug concentration (10 μM), but 
compound 9 only caused 27% worm mortality (Table 8).  
Table 8: In vitro efficacy of target  pyrido[1,2-a]benzimidazoles against adult Schistosoma 
mansoni and newly transformed schistosomula  
 
Compound X Y Z R1 R2 
Antischistosomal 
activity 
Test conc. 10 μM 
(% inhibition) 
 
NTS 
 
Adult S. 
mansoni 
1 
(CN1-034) 
H H H 
 
CF3 46 n.a. 
2 
(CN1-035) 
H H H 
 
CF3 4 n.a. 
4 
(CN1-037) 
H H H  
 
CF3 100 100 
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Compound X Y Z R1 R2 
Antischistosomal 
activity 
Test conc. 10 μM 
(% inhibition) 
 
NTS 
 
Adult S. 
mansoni 
5 
(CN1-038) 
H H H 
 
CF3 64 n.a. 
6 
(CN1-040) 
H H H 
 
CF3 64 n.a. 
7 
(CN1-041) 
H H H 
 
CF3 26 n.a. 
8 
(CN1-042) 
H H H 
 
CF3 45 n.a. 
9 
(CN1-043) 
H H H 
 
CF3 71 27.3 
10 
(CN1-044) 
H H H 
 
CF3 12 n.a. 
11 
(CN1-045) 
H H H 
 
CF3 29 n.a. 
12 
(CN1-048) 
H H H 
 
CF3 20 n.a. 
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Compound X Y Z R1 R2 
Antischistosomal 
activity 
Test conc. 10 μM 
(% inhibition) 
 
      
 
NTS 
 
Adult S. 
mansoni 
      
13 
(CN1-049) 
H H H 
 
CF3 19 n.a. 
H H H 
 
CF3 19 
15 
(CN1-051)a 
H H H 
 
 
35 n.a. 
H H H 
 
 
35 
21 
(CN1-063) 
H H H 
 
CF3 63 n.a. 
      
22 
(CN1-064) 
H H H 
 
CF3 48 n.a. 
23 
(CN1-065) 
H H H 
 
CF3 60 n.a. 
24 
(CN1-066) 
H H H 
 
CF3 100 100 
25 
(CN1-067) 
H H H 
 
CF3 22 n.a. 
26 
(CN1-068) 
H H H 
 
CF3 33 n.a. 
27 
(CN1-069) 
H H H 
 
CF3 67 n.a. 
a, lead compound (TDR44047) 
NTS, newly transformed schistosomula; n.a., not assessed 
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CHAPTER 4: PHYSICOCHEMICAL PROFILING 
 Introduction 4.1
A turbidimetric assay was carried out to evaluate the solubility of target PBI compounds. 
The melting points of the synthesized PBIs were determined to deduce and predict the 
various characteristics of the target compounds, including the strength of the 
intermolecular attractive forces, crystallinity, and solubility. 
 
For the solubility assay, serial dilutions were prepared from 10 mM stock solutions in 96-
well plates in triplicate, at concentrations ranging from 0.25 to 10 mM. A blank well 
containing no drug was included as a reference. From this plate, secondary dilutions of the 
samples were prepared in DMSO and 0.01 M phosphate-buffered saline (PBS, pH 7.4) in 
triplicate, in a second 96-well plate such that the final sample concentrations ranged from 0 
to 200 µM. The plate was incubated at room temperature for 2 h and the absorbance was 
measured at 620 nm using a SpectraMax 340 PC384 microplate reader. This wavelength was 
deliberately selected because organic compounds do not commonly absorb ultraviolet (UV) 
radiation at this wavelength. Therefore, the absorbance of the insoluble particles that 
precipitate out of solution beyond the solubility threshold of the compound was measured. 
 
The absorbance readings obtained were further analyzed by plotting a graph of the 
corrected absorbance against the concentration to determine the compound’s solubility 
profile. The concentration at which the compound deviates from the baseline indicates the 
concentration at which the compound is insoluble, as the solution is turbid. In this kinetic 
turbidimetric assay, compounds with solubility < 1 μM are considered poorly soluble, those 
with solubility between 1 - 100 μM are moderately soluble, and those with solubility >100 
μM are considered highly soluble. DMSO served as the internal standard to exclude 
compound absorption, and two other controls were included: hydrocortisone, which was 
soluble across all concentrations, and reserpine, which displayed moderate solubility (5-10 
μM). These observations confirmed the validity of this solubility assay and the respective 
plots are illustrated in Figures 38 and 39 below.  
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Figure 37: Plot of corrected absorbance versus concentration for hydrocortisone 
 
 
 
 
 
 
 
 
Figure 38: Plot of corrected absorbance versus concentration for reserpine 
The predicted topological polar surface area (TPSA), a predictor of trans-membrane 
permeability and absorption, and calculated log P (cLogP), a measure of the compound’s 
lipophilicity, were determined using ChemDraw version 16.0. The cLogP and TPSA of the 
synthesized compounds ranged from 2.92 to 7.18 and 45.87 to 80.11 Å2, respectively. The 
polar surface area and cLogP properties ranged widely, and guided subsequent syntheses 
from lead compound 15 (TDR44047) to generate a diverse series of compounds whose 
physicochemical profiles are presented in Table 9. 
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Table 9: Calculated LogP, topological polar surface area, and solubility data for pyrido[1,2-                              
a]benzimidazole target compounds 
 
Compound X Y Z R1 R2 cLogP
 TPSA 
(Å2) 
Melting 
point 
(°C) 
Turbid-
imetric 
solubility 
(µM) 
1 
(CN1-034) 
H H H 
 
CF3 5.76 45.87 
 
254-256 
 
5-10 
2 
(CN1-035) 
H H H 
 
CF3 5.61 45.87 
 
267-269 
 
5-10 
3 
(CN1-036) 
H H H 
 
CF3 3.32 54.66 
 
264-266 
 
20-40 
4 
(CN1-037) 
H H H 
 
CF3 5.64 45.87 
 
244-246 
 
5-10 
5 
(CN1-038) 
H H H 
 
CF3 4.50 62.94 
 
255-257 
 
10-20 
6 
(CN1-040) 
H H H 
 
CF3 5.87 45.87 
 
248-250 
 
5-10 
7 
(CN1-041) 
H H H 
 
CF3 5.82 45.87 
 
269-271 
 
5-10 
8 
(CN1-042) 
H H H 
 
CF3 5.15 69.66 
 
259-261 
 
10-20 
9 
(CN1-043) 
H H H 
 
CF3 6.50 45.87 
 
254-256 
 
5-10 
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Compound X Y Z R1 R2 cLogP
 TPSA 
(Å2) 
Melting 
point 
(°C) 
Turbid-
imetric 
solubility 
(µM) 
 
10 
(CN1-044) 
H H H 
 
CF3 5.71 45.87 
 
256-258 
 
5-10 
11 
(CN1-045) 
H H H 
 
CF3 3.67 72.17 
 
278-280 
 
20-40 
12 
(CN1-048) 
H H H 
 
CF3 5.76 45.87 
 
269-271 
 
5-10 
13 
(CN1-049) 
H H H 
 
CF3 5.76 45.87 
 
259-261 
 
5-10 
14 
(CN1-050) 
H H H 
 
CF3 6.11 45.87 
 
254-256 
 
5-10 
15 
(CN1-051)a 
H H H 
 
 
6.54 45.87 246-248 1-5 
16 
(CN1-052) 
H H H 
 
CF3 5.05 69.66 272-273 5-10 
17 
(CN1-059) 
H Cl Cl 
 
CF3 7.02 45.87 264-266 1-5 
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Compound X Y Z R1 R2 cLogP
 TPSA 
(Å2) 
Melting 
point 
(°C) 
Turbid-
imetric 
solubility 
(µM) 
18 
(CN1-060) 
H Cl Cl 
 
CF3 7.06 45.87 258-260 1-5 
19 
(CN1-061) 
H Cl Cl 
 
CF3 7.06 45.87 277-279 1-5 
20 
(CN1-062) 
H Cl Cl 
 
CF3 7.06 45.87 256-258 1-5 
21 
(CN1-063) 
H H H 
 
CF3 5.32 45.87 271-273 5-10 
22 
(CN1-064) 
H H H 
 
CF3 4.11 80.11 260-262 10-20 
23 
(CN1-065) 
H H H 
 
CF3 4.37 58.23 275-277 10-20 
24 
(CN1-066) 
H H H 
 
CF3 4.37 58.23 274-276 10-20 
25 
(CN1-067) 
H H H 
 
CF3 3.61 70.59 256-258 20-40 
26 
(CN1-068) 
H H H 
 
CF3 2.92 71.73 
 
263-265 
 
40-80 
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Compound X Y Z R1 R2 cLogP
 TPSA 
(Å2) 
Melting 
point 
(°C) 
Turbid-
imetric 
solubility 
(µM) 
 
27 
(CN1-069) 
H H H 
 
CF3 6.21 45.87 265-267 1-5 
28 
(CN1-070) 
H H H 
 
CF3 5.40 58.23 266-268 5-10 
29 
(CN1-071) 
H H H 
 
CF3 5.84 45.87 270-272 5-10 
30 
(CN1-072) 
H H H 
 
CF3 3.86 49.11 265-267 10-20 
31 
(CN1-077) 
Cl H Cl 
 
CF3 7.14 45.87 269-271 1-5 
32 
(CN1-078) 
Cl H Cl 
 
CF3 7.18 45.87 273-275 < 5 
33 
(CN1-079) 
H F F 
 
CF3 5.93 45.87 254-256 5-10 
34 
(CN1-080) 
H F F 
 
CF3 5.97 45.87 274-276 1-5 
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 Turbidimetric (kinetic) solubility  4.2
The turbidimetric solubility assay revealed that this series of compounds display low to 
moderate solubility (< 100 µM). This may be due to π-π stacking of the planar tricyclic core. 
The compounds that were soluble contained heteroatoms in their amino side-chains: for 
example, the solubility of compound 21 (5-10 µM) improved with the introduction of 
heteroatoms (compound 25, 20-40 µM). Di-substituted PBI compounds displayed poor 
solubility compared to their unsubstituted parent compounds, because of their high 
lipophilicity resulting from the introduction of chloro and fluoro groups. Introducing a 
carbonyl group to the methylene linker on the piperazine ring, as in compounds 5 (10-20 
µM) and 26 (40-80 µM), resulted in improved solubility. This improvement can be attributed 
to strong hydrogen bonding interactions between the compounds and water, which 
improve compound solubilization. 
 
 
Compound X Y Z R1 R2 cLogP
 TPSA 
(Å2) 
Melting 
point 
(°C) 
Turbid-
imetric 
solubility 
(µM) 
 
35 
(CN1-082) 
H H H 
 
CF3 5.58 72.17 265-267 1-5 
36 
(CN1-083) 
H H H 
 
CF3 3.97 80.01 260-262 20-40 
a, lead compound 
cLogP, calculated LogP; TPSA, topological polar surface area (determined using ChemDraw version 16.0)  
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Compound 1 (5-10 µM) showed improved turbidimetric solubility compared to compound 
15 (1-5 µM). Introducing a trifluoromethyl group in place of the propyl chain at R2 thus 
improved the solubility of lead compound 15. More than 85% of the LHS-unsubstituted 
compounds showed improved solubility compared to compound 15, possibly because of the 
presence of the trifluoromethyl group at R2, as well as that of amine substituents. 
 Melting points 4.3
Compounds in this series displayed relatively high melting points (> 244 °C), possibly 
because of their common structural planar tricyclic core, which promotes intermolecular 
interactions via π-π stacking.  
 Comparison of cLogP, TPSA, and antiplasmodium activity 4.4
LHS-unsubstituted compounds (cLogP 2.92 to 6.50) showed an average solubility range of 
10-20 μM, while the average solubility range of LHS-substituted compounds (cLogP 5.93 - 
7.18) was only 5-10 μM. As expected, introducing di-chlorination and di-fluorination to the 
LHS of the PBI core increased lipophilicity and therefore lowered the aqueous solubility. 
In most cases, compounds with the same TPSA as the reference compound 15 (45.87 Å2) 
displayed relatively high antiplasmodium activity, as shown in compounds 1 (IC50 = 0.17 
µM), 10 (IC50 = 0.09 µM), and 33 (IC50 = 0.01 µM), among others. However, compounds that 
had a higher TPSA than compound 15 (45.87 Å2) displayed lower antiplasmodium activity, 
with the exception of compound 28 (TPSA 58.23 Å2, IC50 = 0.62 µM), which exhibited potent 
antiplasmodium activity. Thus, it is safe to conclude, on the basis of this data, that 
compounds with a similar TPSA to compound 15 favoured antiplasmodium activity of 
piperazinyl PBI analogues.  
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CHAPTER 5: SUMMARY AND FUTURE OUTLOOK 
 General summary and conclusion 5.1
In this dissertation, the design, synthesis, and characterization of piperazine-based PBI 
analogues with various amine side-chain substituents were undertaken. Diverse compounds 
with or without modifications on the benzyl portion of the PBI scaffold were synthesized, 
characterized via 1H and 13C NMR spectroscopy as well as LC-MS, and profiled for 
antiplasmodium and antischistosomal activities. Moreover, towards exploring a potential 
mechanism of action, the analogues were evaluated for β-hematin inhibitory activity. 
Physicochemical properties of target compounds were also determined including solubility 
and melting point. 
Structure-activity and structure-property relationship trends emanating from this work may 
be summarised as follows:  
 LHS di-fluoro substitution led to markedly improved antiplasmodium and β-hematin 
inhibition activity. 
 Generally, there was a positive albeit weak correlation between BHI and 
antiplasmodium activities. 
 Hydrophobic electron-withdrawing Craig plot substituents favoured antiplasmodium 
activity. 
 Compounds bearing methylene- and ethylene-linked R1 moieties (Figure 40) showed 
comparable activities. 
 Introducing a carbonyl group to the methylene linker at R1 or the piperazine ring 
(piperazin-2-one) resulted in enhanced solubility. However, this was accompanied by 
loss of antiplasmodium activity. 
 Regio-isomerism showed no influence on antiplasmodium activity as ortho-, meta-, 
and para-substituted analogues were equipotent. 
 3,5- and 4,5- LHS-dichlorinated analogues displayed comparable activity but reduced 
activity relative to that of the parent unsubstituted analogues. 
 Introducing a cyclohexane saturated substituent at R1 (Figure 40) resulted in high 
antiplasmodium and β-hematin inhibition activities. 
 93 
 
 LHS-substitution reduced turbidimetric solubility. Over 85% of the LHS-unsubstituted 
analogues showed significant improvement in solubility relative to that of lead 
compound 15. 
 Piperazinyl PBIs showed minimal gametocytocidal activity against both early and late 
gametocytes (< 50% inhibition at both 5 μM and 1 μM).  
 Of the 23 compounds that were screened against NTS at a test concentration of 10 
μM, compounds 4, 9, and 24 (Figure 39) displayed > 70% worm mortality. These 
three compounds were further evaluated against adult S. mansoni at the same initial 
concentration, and compounds 4 and 24 resulted in > 70% inhibition of worm 
viability. These frontrunner compounds are prioritised for further IC50 determination. 
 
Figure 39: Chemical structures of compounds 4, 9, and 24 that displayed > 70% worm 
mortality against newly transformed schistosomula at a test concentration of 10 μM 
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Figure 40: SAR Summary of the antiplasmodium and antischistosomal pyrido[1,2-
a]benzimidazoles generated in this study (EWG, electron-withdrawing group; ERG, electron-
releasing group; NTS, newly transformed schistosomula) 
 Future Work 5.2
Based on the identified SAR and SPR, future work suggested towards further profiling and 
optimization of frontrunner leads include: 
 Further studies around the PBI core, to explore structure-activity and structure-
property relationships to produce target compounds with improved drug-likeness 
(Figure 41). 
 IC50 determination in adult S. mansoni, to draw conclusions about the 
antischistosomal activity of these PBI compounds. 
 P. falciparum liver-stage screening, to evaluate stage-specificity and/or multi-stage 
activity.  
 Cytotoxicity screens against the mammalian Chinese Hamster Ovarian (CHO) cell-
line, to assess the compounds’ cytotoxicity and to identify compounds with an 
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acceptable cytotoxicity profile for further evaluation of in vitro metabolic stability. 
Additionally, metabolically stable frontrunner compounds could be assessed in vivo.  
 
Figure 41: Proposed additional SAR strategy to piperazinyl pyrido[1,2-a]benzimidazole 
derivative 33 with potential to improve solubility (HBD, hydrogen-bond donor; HBA, 
hydrogen-bond acceptor; SAR, structure-activity relationship; PBI, pyrido[1,2-
a]benzimidazole; Mwt, molecular weight) 
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CHAPTER 6: EXPERIMENTAL 
 Reagents, Solvents, Materials and Equipment 6.1
The commercially available analytical grade reagents and chemicals were purchased from 
either Sigma-Aldrich or Combi-Blocks and were used without purification. Reactions were 
monitored using Fluka or Merck F254 aluminium-backed pre-coated silica gel thin-layer 
chromatography (TLC) plates, and employing appropriately constituted mobile phases that 
comprised of ethyl acetate (EtOAc) and hexane or methanol (MeOH) and dichloromethane 
(DCM). TLC plates were visualized under ultraviolet light at wavelengths of 254 nm and 365 
nm.  
 
The Agilent LC-MS (liquid chromatography–mass spectrometry) instrument was used to 
determine the compound purity by comparing peak areas, the compound’s molecular ion, 
and the retention time of the synthesized analogues. The LC-MS equipment comprised of 
Agilent 1260® Infinity Binary Pump, Agilent 1260® Infinity Diode Array Detector, Agilent 
1290® Infinity Column Compartment, Agilent 1260® Infinity Autosampler, Agilent 6120® 
Quadrupole LC/MS and Peak Scientific® Genius 1050 Nitrogen Generator. The instrument 
was fitted with a Kinetex Core C18, 2.6 µm, 3 x 50 mm, 100 Å column which was maintained 
at 40 °C. The diode array detector was set to scan eluents at wavelengths in the range of 
210-640 nm with mass spectra acquired using Electron Spray ionization (ESI) and 
Atmospheric Pressure Chemical Ionization (APCI) in the positive or negative mode. An 
injection volume of 2 µL and flow rate of 0.9 mL/min was used with the HPLC (high 
Performance Liquid Chromatography) composition and gradient conditions of the mobile 
phase as indicated in Table 10 below. 
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1H NMR spectra were recorded on a Varian Mercury (300 MHz), a Bruker Ultrashield-Plus 
(400 MHz) spectrometer or a Bruker (600 MHz). 13C NMR spectra were recorded on the 
same instruments at 101 MHz or 151 MHz. NMR samples were prepared using deuterated 
dimethyl sulfoxide (DMSO-d6). The J values represent the coupling constants and are given 
in Hertz (Hz). The multiplicities are abbreviated as s, d, t, m, dd, and ddd which represent 
the presence of a singlet, doublet, triplet, multiplet, doublet of doublets, and doublet of 
doublet of doublets on the 1H NMR spectra, respectively. Melting points were determined 
using the STUART® automatic melting point machine in accordance with manufacturer’s 
instructions.    
 Synthesis and Characterization 6.2
6.2.1 General Procedures and characterization of intermediates 
6.2.1.1 Synthesis of intermediate I  
To a suspension of the appropriately substituted diaminobenzene (1.0 equivalent) in DMF 
(0.7 mL), ethyl 2-cyanoacetate (3.0 equivalents) was added. The resulting reaction mixture 
was heated at 160 °C with stirring and monitored hourly using TLC. When the reaction was 
complete (9 - 12 h), the mixture was cooled to room temperature and the solvent 
evaporated with toluene (3 x 20 mL). The residue was then triturated by stirring in diethyl 
ether (20 mL), filtered and dried in vacuo to furnish the desired 2-benzimidazole 
acetonitrile-based intermediates I (a-c).  
Table 10:  The HPLC mobile phase composition and gradient conditions 
Time (min) % A % B 
Composition 
A B 
0.00-1.00 90 10 10 mM NH4OAc in buffer 
(0.4% acetic acid) 
10 mM NH4OAc (0.4% 
acetic acid) in 90% HPLC 
grade MeOH in H2O 
1.00-3.00 5 95 
3.00-5.00 5 95 
5.00-6.50 90 10 
6.50-7.00 90 10 
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2-(5,7-dichloro-1H-benzo[d]imidazol-2-yl)acetonitrile (I-a) 
Obtained from 3,5-dichlorobenzene-1,2-diamine as a light brown 
solid (0.50 g, 74%); Rf (EtOAc:Hex, 1:1) 0.32; 
1H NMR (300 MHz, 
DMSO-d6) δ 13.17 (s, 1H, H
3), 7.63 (d, J = 1.8 Hz, 1H, H2), 7.39 (d, J = 
1.8 Hz, 1H, H1), 4.43 (s, 2H, H4); 13C NMR (101 MHz, DMSO-d6) 149.2, 
147.9, 143.4, 127.1 (2C), 116.1, 113.5, 110.2, 20.6; HPLC-MS 
(APCI/ESI): Purity = 97%, tR = 2.571 min, m/z [M+H]
+ = 226.0. 
2-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)acetonitrile (I-b) 
Obtained from 4,5-dichlorobenzene-1,2-diamine as a light brown 
solid (0.50 g, 85%); Rf (EtOAc:Hex, 1:1) 0.36; 
1H NMR (300 MHz, 
DMSO-d6) δ 12.82 (s, 1H, H
3), 7.83 (s, 2H, H1,2), 4.41 (s, 2H, H4); 13C 
NMR (101 MHz, DMSO-d6) δ 148.6, 145.1, 143.5, 123.6 (2C), 116.2, 
113.3, 110.2, 19.9; HPLC-MS (APCI/ESI): Purity = 98%, tR = 2.681 
min, m/z [M+H]+ = 226.0.  
2-(5,6-difluoro-1H-benzo[d]imidazol-2-yl)acetonitrile (I-c) 
Obtained from 4,5-difluorobenzene-1,2-diamine as a dark brown 
solid (0.50 g, 64%); Rf (EtOAc:Hex, 3:2) 0.26; 
1H NMR (400 MHz, 
DMSO-d6) δ 12.80 (s, 1H, H
3), 7.62 – 7.45 (m, 2H, H1,2), 4.39 (s, 2H, 
H4); 13C NMR (101 MHz, DMSO-d6) δ 148.5, 148.2, 147.4, 146.1 (2C), 
116.8, 106.1, 101.6, 18.93; HPLC-MS (APCI/ESI): Purity = 97%, tR = 
2.465 min, m/z [M+H]+ = 194.1. 
6.2.1.2 Synthesis of intermediate II 
A mixture of the appropriately substituted benzimidazole acetonitrile (1.0 equivalent), 
ammonium acetate (2.0 equivalents), and ethyl 4,4,4-trifluoro-3-oxobutanoate (1.2 
equivalents) were stirred at 150 °C for 10 h. Reaction mixture was cooled to 70 °C, a 
minimum amount of acetonitrile (15 - 20 mL) added, and the mixture stirred for a further 15 
minutes followed by cooling to room temperature and then on ice. The cooled mixture was 
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filtered and dried to furnish the desired intermediates II (a–d), which were used in 
subsequent steps without further purification. 
1-hydroxy-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (II-a) 
Obtained from 2-(1H-benzo[d]imidazol-2-yl)acetonitrile as a 
light brown solid (0.80 g, 85%), Rf (EtOAc:Hex, 1:1) 0.36; 
1H 
NMR (400 MHz, DMSO-d6) δ 8.59 (dd, J = 8.2, 1.1 Hz, 1H, H
1), 
7.63 (dd, J = 8.3, 1.0 Hz, 1H, H4), 7.61 (ddd, J = 8.2, 7.2, 1.1 Hz, 
1H, H3), 7.45 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H, H2), 6.41 (s, 1H, H5); 
13C NMR (101 MHz, DMSO-d6) δ 168.0, 148.1, 138.5, 132.2, 
127.4, 123.9 (2C), 121.3, 116.7, 114.6, 112.2, 103.2, 98.5; 
HPLC-MS (APCI/ESI): Purity = 98%, tR = 2.628 min, m/z [M-H]
- = 276.1. 
7,9-dichloro-1-hydroxy-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile 
(II-b) 
Obtained from I-a as a light brown solid (0.30 g, 66%), Rf 
(EtOAc:Hex, 3:2) 0.35;   1H NMR (400 MHz, DMSO-d6) δ 8.45 (d, 
J = 2.0 Hz, 1H, H2), 7.64 (d, J = 2.0 Hz, 1H, H1), 6.02 (s, 1H, H3); 
13C NMR (101 MHz, DMSO-d6) δ 169.7, 153.2 (2C), 139.4, 
131.4, 123.9 (2C), 121.4, 120.6, 116.9, 114.4 (2C), 97.5; HPLC-
MS (APCI/ESI): Purity = 98%, tR = 2.784 min, m/z [M-H]
- = 
343.9. 
7,8-dichloro-1-hydroxy-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile 
(II-c) 
Obtained from I-b as a light brown solid (0.30 g, 78%), Rf 
(EtOAc:Hex, 3:2) 0.34;  1H NMR (400 MHz, DMSO-d6) δ 8.61 (s, 
1H, H1), 7.79 (s, 1H, H2), 6.10 (s, 1H, H3); 13C NMR (101 MHz, 
DMSO-d6) δ 169.4, 153.8, 149.1, 143.9, 129.7, 127.4, 124.2, 
120.9, 117.7, 117.2, 116.5 (2C), 96.5; HPLC-MS (APCI/ESI): 
Purity = 98%, tR = 2.750 min, m/z [M-H]
- = 343.9.
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7,8-difluoro-1-hydroxy-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile 
(II-d) 
Obtained from I-c as a brown solid (0.30 g, 80%), Rf 
(EtOAc:Hex, 3:2) 0.40; 1H NMR (400 MHz, DMSO-d6) δ 8.39 (dd, 
J = 11.0, 7.4 Hz, 1H, H1), 7.72 (dd, J = 10.8, 7.3 Hz, 1H, H2), 6.31 
(s, 1H, H3); 13C NMR (101 MHz, DMSO-d6) δ 168.4, 153.2 (2C), 
144.9, 130.0, 127.4, 124.9, 120.7, 117.6, 117.0, 116.5 (2C), 
98.2; HPLC-MS (APCI/ESI): Purity = 98%, tR = 2.650 min, m/z 
[M-H]- = 312.1. 
 
6.2.1.3 Synthesis of intermediate III 
A mixture of the hydroxyl intermediate II (1 equivalent) and POCl3 (20 equivalents) was 
stirred and heated at 130 °C. The reaction was monitored hourly using TLC and completed 
after 8 h. Excess POCl3 was removed under reduced pressure and ice-cold water (20 mL) was 
slowly added to the mixture while stirring, yielding a yellow precipitate. The reaction 
mixture was neutralized with saturated NaHCO3, filtered, and the resulting residue washed 
with ice-cold water (4 x 20 mL), dried in vacuo and used without further purification. 
1-chloro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (III-a) 
Obtained from II-a as a yellow solid (0.60 g, 77%), Rf 
(EtOAc:Hex, 1:1) 0.40; 1H NMR (600 MHz, DMSO-d6) δ 8.78 (dd, 
J = 8.2, 1.0 Hz, 1H, H1), 8.11 (dd, J = 8.2, 1.1 Hz, 1H, H4), 7.81 
(ddd, J = 8.2, 7.2, 1.0 Hz, 1H, H3), 7.79 (s, 1H, H5), 7.63 (ddd, J = 
8.1, 7.1, 1.1 Hz, 1H, H2); 13C NMR (101 MHz, DMSO-d6) δ 158.1, 
147.9, 138.6, 132.3, 127.8, 123.9, 123.5, 121.0 (2C), 116.7, 
114.6, 112.1, 100.3; HPLC-MS (APCI/ESI): Purity = 99%, tR = 
2.829 min, m/z [M+H]+ = 296.1. 
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1,7,9-trichloro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (III-b) 
Obtained from II-b as a yellow solid (0.15 g, 80%), Rf 
(EtOAc:Hex, 1:1) 0.20;  1H NMR (400 MHz, DMSO-d6) δ 8.78 (d, 
J = 2.0 Hz, 1H, H2), 8.09 (d, J = 2.0 Hz, 1H, H1), 7.84 (s, 1H, H3); 
13C NMR (101 MHz, DMSO-d6) δ 163.7, 157.6, 149.9, 143.1, 
139.8, 133.6, 130.5, 126.6 (2C), 121.9, 115.4 (2C), 100.6; HPLC-
MS (APCI/ESI): Purity = 98%, tR = 2.677 min, m/z [M+H]
+ = 
363.9. 
1,7,8-trichloro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (III-c) 
Obtained from II-c as a yellow solid (0.15 g, 84%), Rf 
(EtOAc:Hex, 3:2) 0.42;  1H NMR (400 MHz, DMSO-d6) δ 8.76 (s, 
1H, H1), 8.45 (s, 1H, H2), 7.76 (s, 1H, H3); 13C NMR (101 MHz, 
DMSO-d6) δ 158.7, 150.6, 139.1, 132.9, 130.4, 127.1, 124.8, 
120.6, 117.6 (2C), 114.5, 112.7, 98.0; HPLC-MS (APCI/ESI): 
Purity = 98%,  tR = 2.870 min, m/z [M+H]
+ = 363.9. 
 
1-chloro-7,8-difluoro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile 
(III-d) 
Obtained from II-d as a yellow solid (0.15 g, 71%), Rf 
(EtOAc:Hex, 2:3) 0.46; 1H NMR (400 MHz, DMSO-d6) δ 8.50 (dd, 
J = 11.0, 7.4 Hz, 1H, H1), 7.74 (dd, J = 10.9, 7.3 Hz, 1H, H2), 6.43 
(s, 1H, H3); 13C NMR (101 MHz, DMSO-d6) δ 158.4, 152.2, 150.1, 
143.7, 130.2, 127.6, 124.1, 121.7, 117.9, 117.1, 116.4 (2C), 
100.0; HPLC-MS (APCI/ESI): Purity = 97%, tR = 2.693 min, m/z 
[M+H]+ = 331.9. 
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6.2.2 General Procedures and characterization of final target compounds 
6.2.2.1 Synthesis of target compounds IV 
The stirred mixture of the chlorinated intermediate III (1 equivalent), triethylamine (2 
equivalents), THF (5 mL) and the appropriate amine (1.2 equivalents) were irradiated in a 
microwave at 150 W (55 - 80 °C) for 20 - 60 minutes. The reaction was monitored every 10 
minutes using TLC and LC-MS. THF was removed in vacuo and the residue was puriﬁed by 
column chromatography (SiO2, 10% MeOH: DCM) to furnish target compounds IV (1-36).  
1-(4-(4-fluorobenzyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (1) 
 Obtained from III-a as a yellow solid (0.86 g, 86%); m.p. 254 – 
256 °C; Rf (EtOAc:Hex, 3:7) 0.40;
 1H NMR (400 MHz, DMSO-d6) δ 
8.31 (dd, J = 8.3, 1.0 Hz, 1H, H1), 7.98 (dd, J = 8.3, 1.1 Hz, 1H, H4), 
7.67 (ddd, J = 8.2, 7.1, 1.0 Hz, 1H, H3), 7.54 (dd, J = 8.6, 5.6 Hz, 2H, 
H9), 7.22 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H, H2), 7.11 (dd, J = 9.8, 8.5 
Hz, 2H, H10), 6.85 (s, 1H, H5), 3.64 (s, 2H, H8), 3.52 - 3.44 (m, 4H, 
H6), 2.98 - 2.77 (m, 4H, H7); 13C NMR (101 MHz, DMSO-d6) δ 
159.8, 154.2, 147.8, 145.3, 141.8, 134.5, 131.2, 128.9, 127.4 (2C), 
122.9 (2C), 120.0, 116.6, 115.5 (2C), 115.3, 113.6, 95.3, 61.2, 51.7 
(2C), 46.1 (2C); HPLC-MS (APCI/ESI): Purity = 97%, tR = 3.209 min, 
m/z [M+H]+ = 454.2. 
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1-(4-benzylpiperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (2) 
Obtained from III-a as a yellow solid (0.81 g, 81%); m.p. 267 – 269 
°C; Rf (EtOAc:Hex, 3:7) 0.30;  
1H NMR (400 MHz, DMSO-d6) δ 8.31 
(dd, J = 8.4, 1.0 Hz, 1H, H1), 7.98 (dd, J = 8.3, 1.1 Hz, 1H, H4), 7.67 
(ddd, J = 8.2, 7.2, 1.0 Hz, 1H, H3), 7.54 (ddd, J = 8.1, 7.3, 1.0 Hz, 1H, 
H2), 7.42 - 7.35 (m, 2H, H9), 7.29 - 7.23 (m, 3H, H10,11), 6.85 (s, 1H, 
H5), 3.65 (s, 1H, 2H, H8), 3.09 - 3.02 (m, 4H, H6), 2.67 - 2.52 (m, 4H, 
H7); 13C NMR (101 MHz, DMSO-d6) δ 154.2, 147.8, 145.3, 138.3, 
137.5 (2C), 133.9, 129.4, 128.9 (2C), 127.9, 123.6 (2C), 120.2, 
119.6, 116.6, 113.6, 112.6, 95.3, 62.2, 50.3 (2C), 49.4 (2C); HPLC-
MS (APCI/ESI): Purity = 98%, tR = 3.038 min, m/z [M+H]
+ = 436.1. 
 
1-(piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (3) 
 Obtained from III-a as a yellow solid (0.83 g, 83%); m.p. 264 – 266 
°C; Rf (EtOAc:Hex, 2:3) 0.30; 
1H NMR (400 MHz, DMSO-d6) δ 8.34 
(dd, J = 8.3, 1.1 Hz, 1H, H1), 7.99 (dd, J = 8.2, 1.1 Hz, 1H, H4), 7.68 
(ddd, J = 8.1, 7.1, 1.1 Hz, 1H, H3), 7.56 (ddd, J = 8.4, 7.1, 1.2 Hz, 1H, 
H2), 6.83 (s, 1H, H5), 3.48 - 3.43 (m, 4H, H6), 3.10 - 3.06 (m, 4H, H7); 
13C NMR (101 MHz, DMSO-d6) δ 156.4, 147.8, 145.3, 128.9, 127.3, 
122.8 (2C), 121.2, 119.9, 116.6, 113.6, 112.1, 95.0, 51.2 (2C), 47.6 
(2C); HPLC-MS (APCI/ESI): Purity = 98%, tR = 2.441 min, m/z [M+H]
+ 
= 346.1. 
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1-(4-(4-fluorophenyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (4) 
Obtained from III-a as a yellow solid (0.83 g, 83%); m.p. 244 – 246 
°C; Rf (EtOAc:Hex, 3:7) 0.33; 
1H NMR (400 MHz, DMSO-d6) δ 8.40 
(dd, J = 8.3, 1.1 Hz, 1H, H1), 8.00 (dd, J = 8.3, 1.0 Hz, 1H, H4), 7.68 
(ddd, J = 8.2, 7.1, 1.1 Hz, 1H, H3), 7.55 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H, 
H2), 7.14 (dd, J = 9.8, 8.5 Hz, 2H, H9), 7.09 (dd, J = 8.6, 5.5 Hz, 2H, 
H8), 6.92 (s, 1H, H5), 3.67 - 3.50 (m, 4H, H7), 3.18 - 3.07 (m, 4H, H6); 
13C NMR (101 MHz, DMSO-d6) δ 158.0, 155.7, 154.1, 147.9, 147.7, 
145.3, 136.3, 127.4 (2C), 123.0, 120.0, 118.3, 116.8 (2C), 115.9 
(2C), 113.6, 112.1, 95.4, 48.6 (2C), 46.1 (2C); HPLC-MS (APCI/ESI): 
Purity = 98%, tR = 3.034 min, m/z [M+H]
+ = 440.1. 
 
1-(4-benzoylpiperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (5) 
Obtained from III-a as a yellow solid (0.83 g, 83%); m.p. 255 – 257 
°C; Rf (EtOAc:Hex, 2:3) 0.30; 
1H NMR (400 MHz, DMSO-d6) δ 8.42 
(dd, J = 8.4, 1.0 Hz, 1H, H1), 8.03 - 7.96 (m, 2H, H8), 7.69 (ddd, J = 
8.2, 7.1, 1.1 Hz, 1H, H4), 7.56 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H, H3), 7.51 
- 7.46 (m, 3H, H9,10), 7.44 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H, H2), 6.94 (s, 
1H, H5), 3.64 -3.57 (m, 4H, H7), 3.16 - 3.08 (m, 4H, H6); 13C NMR 
(101 MHz, DMSO-d6) δ 169.8, 153.8, 147.7, 145.3, 136.5, 135.9, 
135.2, 130.3, 130.0 (2C), 128.9 (2C), 123.1 (2C), 120.0, 119.8, 
116.7, 113.5, 112.4, 96.0, 50.2 (2C), 46.0 (2C); HPLC-MS (APCI/ESI): 
Purity = 98%, tR = 2.832 min, m/z [M+H]
+ = 450.2. 
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1-(4-phenethylpiperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (6) 
Obtained from III-a as a yellow solid (0.90 g, 90%); m.p. 248 – 250 
°C; Rf (EtOAc: Hex, 1:1) 0.48; 
1H NMR (400 MHz, DMSO-d6) δ 8.34 
(dd, J = 8.4, 1.0 Hz, 1H, H1), 8.00 (dd, J = 8.2, 1.2 Hz, 1H, H4), 7.69 
(ddd, J = 8.3, 7.1, 1.1 Hz, 1H, H3), 7.56 (ddd, J = 8.5, 7.1, 1.2 Hz, 1H, 
H2), 7.44 - 7.38 (m, 2H, H10), 7.34 - 7.27 (m, 3H, H11,12), 6.87 (s, 1H, 
H5), 3.62 - 3.55 (m, 4H, H7), 3.11 - 3.05 (m, 4H, H6), 2.84 (t, J = 7.4 Hz, 
2H, H8), 2.59 (t, J = 7.2 Hz, 2H, H9); 13C NMR (101 MHz, DMSO-d6) δ 
154.2, 147.8, 145.3, 141.7, 139.1, 135.1, 128.9 (2C), 127.4 (2C), 
126.3, 123.8 (2C), 120.0, 119.3, 116.6, 113.6, 112.1, 95.2, 59.6, 51.8 
(2C), 49.6 (2C), 33.1; HPLC-MS (APCI/ESI): Purity = 98%, tR = 3.081 
min, m/z [M+H]+ = 450.2. 
 
1-(4-(p-tolyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (7) 
Obtained from III-a as a yellow solid (0.67 g, 67%); m.p. 269 – 271 
°C; Rf (EtOAc: Hex, 2:3) 0.34; 
1H NMR (400 MHz, DMSO-d6) δ 8.42 
(dd, J = 8.4, 1.0 Hz, 1H, H1), 8.01 (dd, J = 8.2, 1.1 Hz, 1H, H4), 7.69 
(ddd, J = 8.3, 7.1, 1.1 Hz, 1H, H3), 7.56 (ddd, J = 8.3, 7.1, 1.4 Hz, 1H, 
H2), 7.10 (d, J = 7.9 Hz, 2H, H9), 6.98 (d, J = 8.1 Hz, 2H, H8), 6.90 (s, 
1H, H5), 3.19 - 3.12 (m, 4H, H7), 3.07 - 3.00 (m, 4H, H6), 2.26 (s, 3H, 
H10); 13C NMR (101 MHz, DMSO-d6) δ 154.1, 149.0, 147.8, 145.4, 
136.6, 129.4, 129.0, 127.4 (2C), 123.0 (2C), 120.0, 119.8, 117.7, 
113.4, 112.3 (2C), 111.9, 95.4, 50.4 (2C), 48.5 (2C), 20.4; HPLC-MS 
(APCI/ESI): Purity = 97%, tR = 3.115 min, m/z [M+H]
+ = 436.2. 
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1-(4-(4-cyanophenyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (8) 
Obtained from III-a as a yellow solid (0.86 g, 86%); m.p. 259 – 261 
°C; Rf (EtOAc: Hex, 2:3) 0.27; 
1H NMR (400 MHz, DMSO-d6) δ 8.45 
(dd, J = 8.2, 1.0 Hz, 1H, H1), 8.03 (dd, J = 8.2, 1.0 Hz, 1H, H4), 7.75 
(ddd, J = 8.3, 7.1, 1.4 Hz, 1H, H3), 7.70 (ddd, J = 8.3, 7.2, 1.4 Hz, 1H, 
H2), 7.59 (d, J = 7.8 Hz, 1H, H9), 7.24 (d, J = 7.9 Hz, 2H, H8), 6.92 (s, 
1H, H5), 3.16 - 3.11 (m, 4H, H7), 3.09 - 3.01 (m, 4H, H6); 13C NMR (101 
MHz, DMSO-d6) δ 154.0, 153.4, 145.4, 141.5, 139.0, 135.1, 133.8 
(2C), 123.4 (2C), 120.1, 119.8, 118.0, 117.7,113.7, 112.1, 110.7 (2C), 
102.1, 100.1, 49.9 (2C), 47.3 (2C); HPLC-MS (APCI/ESI): Purity = 97%, 
tR = 2.810 min, m/z [M+H]
+ = 447.2. 
 
3-(trifluoromethyl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (9) 
Obtained from III-a as a yellow solid (0.75 g, 75%); m.p. 254 – 256 
°C; Rf (EtOAc: Hex, 1:1) 0.49; 
1H NMR (400 MHz, DMSO-d6) δ 8.44 
(dd, J = 8.3, 1.0 Hz, 1H, H1), 8.01 (dd, J = 8.3, 1.0 Hz, 1H, H4), 7.70 
(ddd, J = 8.3, 7.2, 1.0 Hz, 1H, H3), 7.62 - 7.54 (m, 3H, H2,9), 7.21 (d, J = 
8.1 Hz, 2H, H8), 6.92 (s, 1H, H5), 3.15 - 2.98 (m, 8H, H6,7); 13C NMR 
(101 MHz, DMSO-d6) δ 154.0, 153.4, 147.4, 144.5, 129.0, 127.1 (2C), 
126.8 (2C), 123.4 (2C), 120.1 (2C), 119.9, 117.7, 115.7 (3C), 114.1, 
96.8, 47.7 (2C), 46.2 (2C); HPLC-MS (APCI/ESI): Purity = 97%, tR = 
3.080 min, m/z [M+H]+ = 490.1. 
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1-(4-cyclohexylpiperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (10) 
Obtained from III-a as a yellow solid (0.67 g, 67%); m.p. 256 – 258 
°C; Rf (EtOAc: Hex, 2:3) 0.40; 1H NMR (400 MHz, DMSO-d6) δ 8.34 
(dd, J = 8.5, 1.0 Hz, 1H, H1), 8.00 (dd, J = 8.2, 1.0 Hz, 1H, H4), 7.73 
(ddd, J = 8.3, 7.2, 1.1 Hz, 1H, H3), 7.57 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H, 
H2), 6.83 (s, 1H, H5), 3.16 - 3.11 (m, 4H, H6), 3.07 - 3.01 (m, 5H, H7,8), 
1.85 - 1.79 (m, 4H, H9), 1.69 - 1.63 (m, 2H, H11), 1.31 - 1.23 (m, 4H, 
H10); 13C NMR (101 MHz, DMSO-d6) δ 158.2, 147.8, 145.4, 136.6, 
129.0, 123.9 (2C), 122.8, 121.2, 120.0, 116.6, 113.5, 100.1, 68.0, 
51.9 (2C), 48.5 (2C), 28.9 (2C), 26.5, 25.1 (2C); HPLC-MS (APCI/ESI): 
Purity = 97%, tR = 2.645 min, m/z [M+H]
+ = 428.2. 
 
1-(4-(furan-2-carbonyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (11) 
Obtained from III-a as a yellow solid (0.91 g, 91%); m.p. 278 – 280 
°C; Rf (MeOH:DCM, 1:9) 0.53; 
1H NMR (400 MHz, DMSO-d6) δ 8.44 
(dd, J = 8.4, 1.1 Hz, 1H, H1), 8.01 (dd, J = 8.2, 1.0 Hz, 1H, H4), 7.83 
(dd, J = 7.8, 1.7 Hz, 1H, H10), 7.70 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H, H3), 
7.57 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H, H2), 7.08 (dd, J = 7.7, 1.9 Hz, 1H, 
H8), 6.72 - 6.64 (m, 1H, H9), 3.92 (s, 1H, H5), 3.23 - 3.16 (m, 4H, H7), 
3.11 - 3.07 (m, 4H, H6); 13C NMR (101 MHz, DMSO-d6) δ 159.1, 
153.7, 147.4, 145.4, 145.2, 136.6, 129.0, 127.4, 123.1 (2C), 120.0, 
119.6, 117.7, 116.6, 116.3, 113.4, 111.8, 95.9, 50.4 (2C), 46.2 (2C); 
HPLC-MS (APCI/ESI): Purity = 97%, tR = 2.767 min, m/z [M+H]
+ = 
440.1. 
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1-(4-(2-fluorobenzyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (12) 
Obtained from III-a as a yellow solid (0.93 g, 93%); m.p. 269 – 271 
°C; Rf (EtOAc: Hex, 2:3) 0.50; 
1H NMR (600 MHz, DMSO-d6) δ 8.33 
(dd, J = 8.3, 1.0 Hz, 1H, H1), 7.99 (dd, J = 8.2 , 1.1 Hz, 1H, H4 ), 7.68 
- 7.53 (m, 2H, H11,12), 7.45 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H, H3), 7.29 
(ddd, J = 8.2, 7.1, 1.0 Hz, 1H, H2), 7.22 - 7.14 (m, 2H, H9,10), 6.87 (s, 
1H, H5), 3.72 (s, 2H, H8), 3.32 - 3.26 (m, 4H, H6), 3.16 - 3.08 (m, 4H, 
H7); 13C NMR (101 MHz, DMSO-d6) δ 160.4, 154.2, 147.7, 145.3, 
132.2, 132.1 (2C), 129.9 (2C), 128.9, 127.4, 124.0, 123.9, 122.8, 
120.0, 116.6, 115.7, 113.6, 95.3, 54.8, 51.7 (2C), 45.2 (2C); HPLC-
MS (APCI/ESI): Purity = 99%, tR = 3.325 min, m/z [M+H]
+ = 454.2. 
 
1-(4-(3-fluorobenzyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (13) 
 Obtained from III-a as a yellow solid (0.90 g, 90%); m.p. 259 – 
261 °C; Rf (EtOAc: Hex, 2:3) 0.44; 
1H NMR (400 MHz, DMSO-d6) δ 
8.35 (dd, J = 8.2, 1.0 Hz, 1H, H1), 7.99 (dd, J = 8.1, 1.1 Hz, 1H, H4), 
7.68 - 7.55 (m, 2H, H11,12), 7.44 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H, H3), 
7.25 (ddd, J = 8.2, 7.1, 1.1 Hz, 1H, H2), 7.19 - 7.13 (m, 2H, H9,10), 
6.85 (s, 1H, H5), 3.72 (s, 2H, H8), 3.27 - 3.21 (m, 4H, H6), 3.19 - 3.08 
(m, 4H, H7); 13C NMR (101 MHz, DMSO-d6) δ 160.0, 154.1, 147.8, 
145.4, 130.5, 130.5 (2C), 129.0 (2C), 128.6, 127.3, 125.1, 123.8,  
122.8, 120.0, 116.6, 115.7, 113.4, 95.3, 54.8, 50.5 (2C), 49.4 (2C); 
HPLC-MS (APCI/ESI): Purity = 96%, tR = 3.319 min, m/z [M+H]
+ = 
454.1  
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1-(4-(4-methylbenzyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (14) 
 Obtained from III-a as a yellow solid (0.78 g, 86%); m.p. 254 – 
256 °C; Rf (EtOAc: Hex, 2:3) 0.50; 
1H NMR (400 MHz, DMSO-d6) δ 
8.35 (dd, J = 8.4, 1.0 Hz, 1H, H1), 7.92 (dd, J = 8.3, 1.1 Hz, 1H, H4), 
7.68 (ddd, J = 8.2, 7.1, 1.1 Hz, 1H, H3), 7.28 (ddd, J = 8.2, 7.1, 1.1 
Hz, 1H, H2), 7.17 (d, J = 7.8 Hz, 2H, H9), 7.12 ( d, J = 7.9, 2H, H10), 
6.34 (s, 1H, H5), 3.67 (s, 2H, H8), 3.30 - 3.23 (m, 4H, H6), 3.18 - 
3.09 (m, 4H, H7), 2.31 (s, 3H, H11); 13C NMR (101 MHz, DMSO-d6) 
δ 160.0, 154.9, 147.2, 145.6, 141.8, 135.0, 131.4, 128.5, 127.6 
(2C), 122.9 (2C), 120.5, 116.3, 115.3 (2C), 115.0, 113.7, 95.9, 
61.5, 51.8 (2C), 47.1 (2C), 21.0; HPLC-MS (APCI/ESI): Purity = 
98%, tR = 3.370 min, m/z [M+H]
+ = 450.2. 
1-(4-(4-fluorobenzyl)piperazin-1-yl)-3-propylbenzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (15) 
Obtained from III-a as a yellow solid (0.88 g, 88%); m.p. 246 – 248 
°C; Rf (EtOAc: Hex, 2:3) 0.50; 
1H NMR (400 MHz, DMSO-d6) δ 8.29 
(dd, J = 8.3, 1.1 Hz, 1H, H1), 7.87 (dd, J = 8.1, 1.1 Hz, 1H, H4), 7.56 
(ddd, J = 8.2, 7.2, 1.1 Hz, 1H, H3), 7.47 (dd, J = 8.5, 5.1 Hz, 2H, 
H12), 7.43 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H, H2), 7.15 (dd, J = 9.8, 8.6 
Hz, 2H, H13), 6.64 (s, 1H, H5), 3.64 (s, 2H, H11), 3.52 - 3.44 (m, 4H, 
H9), 3.10 (t, J = 7.0 Hz, 2H, H6), 3.01 - 2.87 (m, 4H, H10), 1.86 - 1.79 
(m, 2H, H7), 1.23 (t, J = 7.3 Hz, 3H, H8); 13C NMR (101 MHz, DMSO-
d6) δ 159.8, 154.2, 147.8, 145.3, 141.8, 134.5, 131.2, 128.9, 127.4 
(2C), 122.9 (2C), 120.0, 116.6, 115.5 (2C), 113.6, 100.8, 64.4, 54.9 
(2C), 48.7 (2C), 34.9, 23.6, 15.9; HPLC-MS (APCI/ESI): Purity = 
98%, tR = 3.150 min, m/z [M+H]
+ = 428.2.
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1-(4-(4-cyanobenzyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (16) 
Obtained from III-a as a yellow  solid (0.80 g, 80 %); m.p. 272 – 
274 °C; Rf (EtOAc: Hex, 2:3) 0.48; 
1H NMR (400 MHz, DMSO-d6) δ 
8.35 (dd, J = 8.4, 1.0 Hz, 1H, H1), 8.00 (dd, J = 8.3, 1.1 Hz, 1H, H4), 
7.82 (d, J = 8.1 Hz, 2H, H10), 7.71 (ddd, J = 8.3, 7.1, 1.0 Hz, 1H, H3), 
7.63 (d, J = 8.1 Hz, 2H, H9), 7.55 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H, H2), 
6.83 (s, 1H, H5), 3.51 (s, 2H, H8), 3.44 - 3.38 (m, 4H, H6), 2.89 - 
2.74 (m, 4H, H7); 13C NMR (101 MHz, DMSO-d6) δ 158.0, 154.6, 
147.8, 145.4, 130.7 (2C), 129.3 (2C), 128.5, 127.5, 125.8, 123.4,  
122.2, 120.1, 118.9 117.0, 115.5, 113.6, 112.9, 96.1, 54.6, 50.6 
(2C), 49.2 (2C); HPLC-MS (APCI/ESI): Purity = 97%, tR = 2.904 min, 
m/z [M+H]+ = 461.2. 
7,8-dichloro-1-(4-cyclohexylpiperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (17) 
Obtained from III-c as a yellow solid (0.66 g, 66%); m.p. 264 – 266 
°C; Rf (EtOAc: Hex, 2:3) 0.50; 
1H NMR (300 MHz, DMSO-d6) δ 8.83 
(s, 1H, H1), 8.34 (s, 1H, H2), 6.78 (s, 1H, H3), 3.16 - 3.11 (m, 4H, H4), 
3.07 - 3.01 (m, 5H, H5,6), 1.87 - 1.79 (m, 4H, H7), 1.68 - 1.63 (m, 
2H, H9), 1.37 - 1.31 (m, 4H, H8);  13C NMR (101 MHz, DMSO-d6) δ 
158.2, 147.8, 145.4, 141.6, 133.0, 127.9 (2C), 120.8, 118.0 (2C), 
117.6, 114.5, 100.0, 70.0, 50.9 (2C), 48.0 (2C), 29.0 (2C), 26.3, 
25.6 (2C); HPLC-MS (APCI/ESI): Purity = 96%, tR = 3.052 min, m/z 
[M+H]+ = 496.1. 
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7,8-dichloro-1-(4-(4-fluorobenzyl)piperazin-1-yl)-3-propylbenzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (18) 
Obtained from III-c as a yellow solid (0.82 g, 82%); m.p. 258 – 
260 °C; Rf (EtOAc: Hex, 1:1) 0.33; 
1H NMR (400 MHz, DMSO-
d6) δ 8.29 (s, 1H, H
1), 7.98 (s, 1H, H2), 7.58 (dd, J = 8.3, 5.4 Hz, 
2H, H7), 7.26 (dd, J = 9.8, 8.4 Hz, 2H, H8), 6.85 (s, 1H, H3), 3.65 
(s, 2H, H6), 3.78 - 3.57 (m, 4H, H4), 3.22 - 3.14 (m, 4H, H5); 13C 
NMR (101 MHz, DMSO-d6) δ 159.8, 154.2, 148.8, 146.3, 143.8, 
134.5, 131.2, 128.9 (2C), 127.3 (2C), 121.9, 120.3, 116.6, 
115.6 (2C), 115.3, 113.6, 98.3, 70.2, 51.7 (2C), 46.1 (2C); 
HPLC-MS (APCI/ESI): Purity = 97%, tR = 3.262 min, m/z [M+H]
+ 
= 522.1. 
 
7,8-dichloro-1-(4-(3-fluorobenzyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo 
[1,2-a]pyridine-4-carbonitrile (19) 
Obtained from III-c as a yellow solid (0.72 g, 72%); m.p. 277 – 
279 °C;  Rf (EtOAc: Hex, 2:3) 0.50; 
1H NMR (300 MHz, DMSO-d6) 
δ 8.38 (s, 1H, H1), 8.02 (s, 1H, H2), 7.58 - 7.52 (m, 2H, H9,10), 7.28 
- 7.19 (m, 2H, H7,8), 6.78 (s, 1H, H3), 3.72 (s, 2H, H6), 3.71 - 3.58 
(m, 4H, H4), 3.15 - 3.03 (m, 4H, H5); 13C NMR (101 MHz, DMSO-
d6) δ 159.5, 154.7, 148.5, 146.0, 143.9, 134.5, 131.2, 128.1, 
127.7, 126.9, 122.0 (2C), 120.3, 119.6, 116.7 (2C), 115.1, 112.7, 
98.3, 60.9, 52.7 (2C), 45.6 (2C); HPLC-MS (APCI/ESI): Purity = 
97%, tR = 3.415 min, m/z [M+H]
+ = 522.1. 
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7,8-dichloro-1-(4-(2-fluorobenzyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo 
[1,2-a]pyridine-4-carbonitrile (20) 
Obtained from III-c as a yellow solid (0.93 g, 93%); m.p. 256 – 
258 °C; Rf (EtOAc: Hex, 2:3) 0.50; 
1H NMR (400 MHz, DMSO-d6) 
δ 8.35 (s, 1H, H1), 8.27 (s, 1H, H2), 7.58 - 7.33 (m, 2H, H9,10), 
7.18 (m, 2H, H7,8), 6.87 (s, 1H, H3), 3.82 (s, 2H, H6), 3.78 - 3.61 
(m, 4H, H4), 3.29 - 3.18 (m, 4H, H5); 13C NMR (101 MHz, DMSO-
d6) δ 159.6, 154.1, 149.0, 146.8, 142.9, 133.5, 130.9, 129.1, 
126.9 (2C), 122.0 (2C), 120.3, 119.6, 116.7, 115.9, 115.1, 
112.7, 98.3, 60.9, 52.7 (2C), 45.6 (2C); HPLC-MS (APCI/ESI): 
Purity = 97%, tR = 3.347 min, m/z [M+H]
+ = 522.1. 
 
 
1-(4-phenylpiperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (21) 
Obtained from III-a as a yellow solid (0.93 g, 93%); m.p. 271 – 273 
°C; Rf
 (EtOAc: Hex, 2:3) 0.47; 1H NMR (400 MHz, DMSO-d6) δ 8.29 
(dd, J = 8.2 Hz, 1.0Hz, 1H, H1), 7.97 (dd, J = 8.3, 1.1 Hz, 1H, H4), 
7.67 (ddd, J = 8.2, 7.2, 1.0 Hz, 1H, H3), 7.54 (ddd, J = 8.1, 7.1, 1.0 
Hz, 1H, H2), 7.42 - 7.35 (m, 2H, H8), 7.22 - 7.14 (m, 3H, H9,10), 6.77 
(s, 1H, H5), 3.09 - 3.02 (m, 4H, H6), 2.67 - 2.52 (m, 4H, H7); 13C NMR 
(101 MHz, DMSO-d6) δ 157.2, 148.8, 145.6, 138.7, 137.6, 135.0, 
129.9, 128.1 (2C), 127.4, 123.9 (2C), 120.9, 119.6, 117.3 (2C), 
114.6, 112.4, 98.1, 52.6 (2C), 50.7 (2C); HPLC-MS (APCI/ESI): Purity 
= 98%, tR = 3.179 min, m/z [M+H]
+ = 422.2. 
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1-(4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (22) 
Obtained from III-a as a yellow solid (0.88 g, 88%); m.p. 260 – 262 
°C; Rf (MeOH: DCM, 0.5:9.5) 0.45; 
1H NMR (400 MHz, DMSO-d6) δ 
8.44 (dd, J = 8.5, 1.0 Hz, 1H, H1), 8.01 (dd, J = 8.4, 1.1 Hz, 1H, H4), 
7.69 (ddd, J = 8.4, 7.2, 1.0 Hz, 1H, H3 ), 7.56 (ddd, J = 8.6, 7.1, 1.4 Hz, 
1H, H2), 7.21 (d, J = 8.0 Hz, 2H, H8), 7.04 (d, J = 8.1 Hz, 2H, H9), 6.90 
(s, 1H, H5), 3.42 - 3.36 (m, 4H, H7), 3.26 (s, 3H, H10), 3.12 - 3.04 (m, 
4H, H6); 13C NMR (101 MHz, DMSO-d6) δ 157.9, 149.6, 145.9, 138.9, 
137.2, 135.6, 130.7, 128.4 (2C), 127.1, 123.6 (2C), 120.3, 119.5, 
117.2 (2C), 115.1, 113.4, 97.9, 52.7 (2C), 51.1 (2C), 49.1; HPLC-MS 
(APCI/ESI): Purity = 98%, tR = 2.911 min, m/z [M+H]
+ = 500.1. 
 
 
 
1-(4-(pyridin-2-yl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (23) 
Obtained from III-a as a yellow solid (0.91 g, 91%); m.p. 275 – 277 
°C; Rf (EtOAc: Hex, 1:1) 0.32; 
1H NMR (400 MHz, DMSO-d6) δ 8.45 
(dd, J = 8.4, 1.0 Hz, 1H, H1), 8.18 (dd, J = 8.1, 1.1 Hz, 1H, H8), 8.01 
(dd, J = 8.5, 1.1 Hz, 1H, H4), 7.70 (ddd, J = 8.0, 7.2, 1.1 Hz, 1H, H10), 
7.61 (ddd, J = 8.3, 7.1, 1.0 Hz, 1H, H3 ), 7.55 (ddd, J = 8.6, 7.1, 1.4 Hz, 
1H, H2), 6.99 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H, H9), 6.92 (dd, J = 8.0, 1.2 
Hz, 1H, H11), 6.89 (s, 1H, H5), 3.47 - 3.40 (m, 4H, H7), 3.22 - 3.18 (m, 
4H, H6); 13C NMR (101 MHz, DMSO-d6) δ 159.9, 157.7, 150.6, 147.6, 
145.8, 138.6, 135.7, 131.1, 129.1, 127.6, 123.1 (2C), 121.2, 119.9, 
117.4, 115.2, 105.8, 98.8, 52.8 (2C), 51.2 (2C); HPLC-MS (APCI/ESI): 
Purity = 97%, tR = 2.916 min, m/z [M+H]
+ = 423.2. 
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1-(4-(pyridin-4-yl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (24) 
Obtained from III-a as a yellow solid (0.90 g, 90%); m.p. 274 – 276 
°C;  Rf (EtOAc: Hex, 2:3) 0.50; 
1H NMR (400 MHz, DMSO-d6) δ 8.45 
(dd, J = 8.5, 1.0 Hz, 1H, H1), 8.32 (d, J = 8.2 Hz, 2H, H9), 8.01 (dd, J = 
8.2, 1.0 Hz, 1H, H4), 7.71 (ddd, J = 8.3, 7.1, 1.0 Hz, 1H, H3 ), 7.56 
(ddd, J = 8.4, 7.1, 1.2 Hz, 1H, H2), 7.17 (d, J = 8.4 Hz, 2H, H8), 6.92 (s, 
1H, H5), 3.69 - 3.65 (m, 4H, H7), 3.19 - 3.14 (m, 4H, H6); 13C NMR 
(101 MHz, DMSO-d6) δ 159.6, 157.5, 151.6 (2C), 147.6, 145.8, 136.4, 
131.7, 129.1, 127.2, 123.8 (2C), 121.3, 119.4, 116.8, 105.8 (2C), 
98.8, 52.8 (2C), 51.2 (2C); HPLC-MS (APCI/ESI): Purity = 97%, tR = 
2.588 min, m/z [M+H]+ = 423.2. 
 
1-(4-(pyrazin-2-yl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (25) 
Obtained from III-a as a yellow solid (0.63 g, 63%); m.p. 256 – 258 
°C; Rf (EtOAc: Hex, 2:3) 0.50; 
1H NMR (600 MHz, DMSO-d6) δ 8.39 
(dd, J = 8.3, 1.0 Hz, 1H, H1), 8.18 (d, J = 8.0 Hz, 1H, H10), 8.14 - 8.11 
(m, 2H, H8,9), 8.01 (dd, J = 8.3, 1.1 Hz, 1H, H4), 7.94 (ddd, J = 8.3, 
7.1, 1.0 Hz, 1H, H3), 7.70 (ddd, J = 8.2, 7.1, 1.0 Hz, 1H, H2), 6.94 (s, 
1H, H5), 3.69 - 3.58 (m, 4H, H7), 3.18 - 3.08 (m, 4H, H6); 13C NMR 
(151 MHz, DMSO-d6) δ 159.6, 157.5, 151.6, 147.6, 145.8, 136.4, 
134.8, 132.1, 130.7, 128.9, 126.8, 122.9 (2C), 121.4, 117.1, 113.8, 
98.6, 52.8 (2C), 51.6 (2C); HPLC-MS (APCI/ESI): Purity = 98%, tR = 
3.008 min, m/z [M+H]+ = 424.1. 
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1-(3-oxopiperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile 
(26) 
 Obtained from III-a as a yellow solid (0.79 g, 79%); m.p. 263 – 265 
°C; Rf (MeOH: DCM, 0.5:9.5) 0.45; 
1H NMR (300 MHz, DMSO-d6) δ 
8.30 (dd, J = 8.3, 1.0 Hz, 1H, H1), 8.18 (dd, J = 8.2, 1.1 Hz, 1H, H4), 
7.69 (ddd, J = 8.3, 7.1, 1.1 Hz, 1H, H3), 7.54 (ddd, J = 8.4, 7.1, 1.2 Hz, 
1H, H2), 6.83 (s, 1H, H5), 4.08 (s, 2H, H7), 3.33 - 3.27 (m, 2H, H8), 
3.16 - 3.09 (m, 2H, H6). 13C NMR (101 MHz, DMSO-d6) δ 158.8, 
155.9, 147.7, 144.9, 128.9, 126.8, 123.1 (2C), 122.2, 119.7, 115.7, 
113.3, 112.1, 98.0, 58.7, 56.8, 39.6; HPLC-MS (APCI/ESI): Purity = 
98%, tR = 2.588 min, m/z [M+H]
+ = 360.1. 
 
1-(4-(4-chlorophenyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (27) 
 Obtained from III-a as a yellow solid (0.77 g, 77%); m.p. 265 – 267 
°C; Rf (EtOAc: Hex, 2:3) 0.44; 
1H NMR (600 MHz, DMSO-d6) δ 8.41 
(dd, J = 8.4, 1.0 Hz, 1H, H1), 8.01 (dd, J = 8.3, 1.1 Hz, 1H, H4), 7.69 
(ddd, J = 8.2, 7.0, 1.0 Hz, 1H, H3), 7.56 (ddd, J = 8.4, 7.0, 1.2 Hz, 1H, 
H2), 7.25 (d, J = 8.0 Hz, 2H, H9), 7.07 (d, J = 8.1 Hz, 2H, H8), 6.93 (s, 
1H, H5), 3.19 - 3.14 (m, 4H, H7), 3.06 - 3.02 (m, 4H, H6); 13C NMR 
(151 MHz, DMSO-d6) δ 156.9, 149.6, 147.1, 144.9, 141.2, 135.9, 
128.7 (2C), 125.1, 123.8 (2C), 120.6, 119.4, 117.2, 115.5(2C), 114.6, 
112.4, 97.9, 51.6 (2C), 49.1 (2C); HPLC-MS (APCI/ESI): Purity = 98%, 
tR = 3.375 min, m/z [M+H]
+ = 456.1. 
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3-(trifluoromethyl)-1-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)benzo[4,5]imidazo 
[1,2-a]pyridine-4-carbonitrile (28) 
Obtained from III-a as a yellow solid (0.65 g, 65%); m.p. 266 – 268 
°C; Rf (EtOAc: Hex, 2:3) 0.43; 
1H NMR (400 MHz, DMSO-d6) δ 8.50 (s, 
1H, H10), 8.46 (dd, J = 8.4, 1.0 Hz, 1H, H1), 8.02 (d, J = 8.0 Hz, 1H, H9 ), 
7.89 (dd, J = 8.3, 1.1 Hz, 1H, H4), 7.70 (ddd, J = 8.3, 7.1, 1.1 Hz, 1H, 
H3), 7.56 (ddd, J = 8.4, 7.1, 1.2 Hz, 1H, H2), 7.05 (d, J = 8.1 Hz, 1H, 
H8), 6.94 (s, 1H, H5), 3.28 - 3.25 (m, 4H, H7), 3.22 - 3.16 (m, 4H, H6); 
13C NMR (101 MHz, DMSO-d6) δ 157.6, 154.6, 149.6, 145.8, 139.4, 
137.4, 133.7, 128.4, 125.1, 123.2 (2C), 121.0, 120.4, 119.3, 117.8, 
115.6, 113.8, 110.8, 98.8, 51.3 (2C), 50.1 (2C); HPLC-MS (APCI/ESI): 
Purity = 98%, tR = 3.227 min, m/z [M+H]
+ = 491.1. 
 
 
1-(4-(2,4-difluorophenyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (29) 
 Obtained from III-a as a yellow solid (0.84g, 84%); m.p. 270 – 272 
°C; Rf (EtOAc: Hex, 2:3) 0.48; 
1H NMR (400 MHz, DMSO-d6) δ 8.43 
(dd, J = 8.4, 1.0 Hz, 1H, H1), 8.02 (dd, J = 8.2, 1.0 Hz, 1H, H4), 7.70 
(ddd, J = 8.3, 7.1, 1.0 Hz, 1H, H3), 7.60 (ddd, J = 8.4, 7.1, 1.1 Hz, 1H, 
H2), 7.32 - 7.24 (m, 2H, H8,9), 7.09 – 7.04 (m, 1H, H10), 6.97 (s, 1H, 
H5), 3.65 - 3.57 (m, 4H, H7), 3.15 - 3.07 (m, 4H, H6); 13C NMR (101 
MHz, DMSO-d6) δ 158.9, 152.6, 150.5, 145.1, 144.6, 141.4, 136.7, 
129.9, 123.8 (2C), 122.1, 121.3, 119.4, 117.1, 116.8, 113.5, 111.9, 
105.8, 98.8, 52.8 (2C), 51.2 (2C); HPLC-MS (APCI/ESI): Purity = 
98%, tR = 3.188 min, m/z [M+H]
+ = 458.1. 
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1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (30) 
 Obtained from III-a as a yellow solid (0.67 g, 67%); m.p. 265 – 
267 °C;  Rf (EtOAc: Hex, 1:1) 0.28; 
1H NMR (400 MHz, DMSO-d6) δ 
8.31 (dd, J = 8.4, 1.0 Hz, 1H, H1), 7.99 (dd, J = 8.2, 1.0 Hz, 1H, H4), 
7.72 (ddd, J = 8.3, 7.2, 1.1 Hz, 1H, H3), 7.55 (ddd, J = 8.4, 7.1, 1.2 
Hz, 1H, H2), 6.84 (s, 1H, H5), 3.26 - 3.19 (m, 4H, H6), 3.16 - 3.11 
(m, 1H, H8), 3.07 - 3.01 (m, 4H, H7), 2.76 - 2.62 (m, 4H, H10), 2.34 
(s, 3H, H11), 1.74 - 1.65 (m, 4H, H9); 13C NMR (101 MHz, DMSO-d6) 
δ 158.2, 149.7, 146.4, 138.8, 130.0, 123.9 (2C), 121.5, 120.8, 
119.9, 116.6, 113.5, 100.7, 75.0, 53.9 (2C), 51.5 (2C), 48.9 (2C), 
43.5, 29.1 (2C); HPLC-MS (APCI/ESI): Purity = 98%, tR = 2.512 min, 
m/z [M+H]+ = 443.2. 
 
7,9-dichloro-1-(4-cyclohexylpiperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (31) 
Obtained from III-b as a yellow solid (0.91 g, 91%); m.p. 269 – 
271 °C; Rf (EtOAc: Hex, 2:3) 0.40; 
1H NMR (400 MHz, DMSO-d6) δ 
8.23 (d, J = 2.1 Hz, 1H, H2), 7.96 (d, J = 2.0 Hz, 1H, H1), 6.98 (s, 1H, 
H3), 3.24 - 3.17 (m, 4H, H4), 3.07 - 3.01 (m, 5H, H5,6), 1.92 - 1.84 
(m, 4H, H7), 1.65 - 1.57 (m, 2H, H9), 1.38 - 1.31 (m, 4H, H8); 13C 
NMR (101 MHz, DMSO-d6) δ 157.8 148.4, 146.5, 142.6, 133.0, 
127.9, 124.0, 122.8, 121.2, 119.0, 117.6, 114.5, 100.0, 63.0, 50.9 
(2C), 48.0 (2C), 29.0(2C), 26.3, 25.6 (2C); HPLC-MS (APCI/ESI): 
Purity = 98%, tR = 3.204 min, m/z [M+H]
+ = 496.1. 
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7,9-dichloro-1-(4-((5-fluoropyridin-2-yl)methyl)piperazin-1-yl)-3-(trifluoromethyl)benzo 
[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (32) 
Obtained from III-b as a yellow solid (0.76 g, 76%); m.p. 273 – 
275 °C; Rf (EtOAc: Hex, 2:3) 0.44; 
1H NMR (400 MHz, DMSO-
d6) δ 8.23 (d, J = 2.1 Hz, 1H, H
2), 7.92 (d, J = 2.1 Hz, 1H, H1), 
7.61 (dd, J = 8.6, 5.3 Hz, 2H, H7), 7.23 (dd, J = 9.8, 8.6 Hz, 2H, 
H8), 6.85 (s, 1H, H3), 3.63 (s, 2H, H6), 3.54 - 3.47 (m, 4H, H4), 
2.78 - 2.72 (m, 4H, H5). Yellow solid (0.82 g, 82%); 13C NMR 
(101 MHz, DMSO-d6) δ 158.9, 154.6, 148.4, 145.7, 144.1, 
135.5, 132.2, 129.9, 128.1, 127.3 (2C), 122.9, 120.3, 116.6, 
115.8 (2C), 115.5, 113.1, 98.8, 61.4, 51.6 (2C), 46.5 (2C); 
HPLC-MS (APCI/ESI): Purity = 98%, tR = 3.498 min, m/z [M+H]
+ 
= 522.0. 
 
1-(4-cyclohexylpiperazin-1-yl)-7,8-difluoro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (33) 
Obtained from III-d as a yellow solid (0.74 g, 74%); m.p. 254 – 
256 °C; Rf (EtOAc: Hex, 2:3) 0.33; 
1H NMR (400 MHz, DMSO-d6) δ 
8.49 (dd, J = 11.0, 7.4 Hz, 1H, H1), 7.70 (dd, J = 10.8, 7.2 Hz, 1H, 
H2), 6.71 (s, 1H, H3), 3.77 - 3.56 (m, 4H, H4), 3.31 - 3.24 (m, 5H, 
H5,6), 1.94 - 1.88 (m, 4H, H7), 1.67 - 1.56 (m, 2H, H9), 1.33 - 1.20 
(m, 4H, H8); 13C NMR (101 MHz, DMSO-d6) δ 158.2, 147.8 (2C), 
145.4, 141.6, 136.0, 131.9, 121.8, 119.0, 117.6, 107.7 (2C), 98.8, 
69.0, 50.6 (2C), 48.5 (2C), 29.0 (2C), 26.3, 25.6 (2C); HPLC-MS 
(APCI/ESI): Purity = 98%, tR = 2.946 min, m/z [M+H]
+ = 464.2. 
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7,8-difluoro-1-(4-(4-fluorobenzyl)piperazin-1-yl)-3-propylbenzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (34) 
Obtained from III-d as a yellow solid (0.73 g, 73%); m.p. 274 – 
276 °C;  Rf (EtOAc: Hex, 2:3) 0.40; 
1H NMR (400 MHz DMSO-d6) δ 
8.48 (dd, J = 10.8, 7.4 Hz, 1H, H1), 7.78 (dd, J = 10.8, 7.3 Hz, 1H, 
H2), 7.57 (dd, J = 8.5, 5.3 Hz, 2H, H7), 7.28 (dd, J = 10.0, 8.5 Hz, 
2H, H8), 6.65 (s, 1H, H3), 3.65 (s, 2H, H6), 3.84 - 3.76 (m, 4H, H4), 
3.62 - 3.39 (m, 4H, H5); 13C NMR (101 MHz, DMSO-d6) δ 159.9, 
155.2, 145.8 (2C), 146.3, 143.8, 134.5, 131.2, 128.9, 127.9 (2C), 
120.3, 116.6, 115.7 (2C), 113.6, 105.6 (2C), 98.1, 67.8, 51.9 (2C), 
47.7 (2C); HPLC-MS (APCI/ESI): Purity = 98%, tR = 2.904 min, m/z 
[M+H]+ = 490.1. 
 
Methyl 4-((4-(4-cyano-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridin-1-yl)piperazin-
1-yl)methyl)benzoate (35) 
 Obtained from III-a as a yellow solid (0.60 g, 60%); m.p. 
265 – 267 °C; Rf (EtOAc: Hex, 2:3) 0.40; 
1H NMR (400 MHz, 
DMSO-d6) δ 8.54 (dd, J = 8.3, 1.0 Hz, 1H, H
1), 8.34 (d, J = 
8.2 Hz, 2H, H10), 7.98 (dd, J = 8.2, 1.1 Hz, 1H, H4), 7.90 (ddd, 
J = 8.3, 7.1, 1.1 Hz, 1H, H3), 7.68 (ddd, J = 8.3, 7.2, 1.4 Hz, 
1H, H2), 7.55 (d, J = 8.1 Hz, 2H, H9), 6.86 (s, 1H, H5), 3.87 (s, 
3H, H11), 3.77 (s, 2H, H8), 3.29 - 3.19 (m, 4H, H6), 3.16 - 2.94 
(m, 4H, H7); 13C NMR (101 MHz, DMSO-d6) δ 159.7, 157.2, 
146.8, 145.3, 143.6, 140.1, 138.3, 134.5 (2C), 131.9 (2C), 
128.1 (2C), 127.8, 124.6, 121.2, 119.6, 116.6, 113.6, 98.3, 
64.2, 55.5 (2C), 51.2, 49.9 (2C); HPLC-MS (APCI/ESI): Purity 
= 97%, tR = 2.985 min, m/z [M+H]
+ = 494.1. 
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1-(4-(4-(methylsulfonyl)benzyl)piperazin-1-yl)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (36) 
Obtained from III-a as a yellow solid (0.73 g, 73%); m.p. 260 
– 262 °C; Rf (EtOAc: Hex, 2:3) 0.40; 
1H NMR (400 MHz, 
DMSO-d6) δ 8.35 (dd, J = 8.3, 1.0 Hz, 1H, H
1), 8.00 (dd, J = 
8.2, 1.1 Hz, 1H, H4), 7.90 (d, J = 8.2 Hz, 2H, H10), 7.70 (d, J = 
8.1 Hz, 2H, H9), 7.65 (ddd, J = 8.3, 7.1, 1.0 Hz, 1H, H3), 7.54 
(ddd, J = 8.3, 7.2, 1.4 Hz, 1H, H2), 6.86 (s, 1H, H5), 3.56 (s, 2H, 
H8),   3.42 - 3.36 (m, 4H, H7), 3.20 (s, 3H, H11), 3.12 - 2.97 (m, 
4H, H6); 13C NMR (101 MHz, DMSO-d6) δ 156.7, 145.6, 142.9, 
139.9, 138.3, 135.6, 130.7, 128.4(2C), 127.1, 123.6 (2C), 
120.3, 119.5, 117.2 (2C), 115.1, 113.4, 97.9, 66.5, 53.9 (2C), 
48.2 (2C), 47.8; HPLC-MS (APCI/ESI): Purity = 98%, tR = 2.990 
min, m/z [M+H]+ = 514.1. 
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6.2.3 Pharmacological Activity  
6.2.3.1 In vitro Antiplasmodium activity  
The test samples were tested in triplicate on one occasion against chloroquine-sensitive 
NF54 strain of Plasmodium falciparum. Continuous in vitro cultures of asexual erythrocyte 
stages of P. falciparum were maintained using a modified version of the Trager and Jensen 
method.1 Quantitative assessment of antiplasmodium activity in vitro was determined using 
the parasite lactate dehydrogenase assay.2 The test samples were prepared to a 20 mg/ml 
stock solution in 100% DMSO. Samples were tested as suspensions if not completely 
dissolved. Stock solutions were stored at -20 °C pending further dilution on the day of the 
experiment. Chloroquine (CQ) and artesunate served as reference drugs in all experiments. 
A full dose-response was performed for all test compounds to determine the concentration 
inhibiting 50% of parasite growth to give the IC50 value. Test compounds were initially tested 
at a concentration of 100 μg/ml, which was then serially diluted 2-fold to give 10 
concentrations; 0.2 μg/ml being the lowest one. The same dilution technique was used for 
all samples. Reference drugs were tested at a starting concentration of 1000 ng/ml. The 
highest concentration of solvent to which the parasites were exposed had no measurable 
effect on parasite viability. The IC50 values were obtained using a non-linear dose-response 
curve fitting analysis using GraphPad Prism v.4.0 software. 
6.2.3.2 In vitro Antischistosomal activity  
6.2.3.2.1 Screening on Newly Transformed Schistosomula (NTS)  
S. mansoni cercariae were mechanically transformed to NTS.3  Snails were exposed to light 
to encourage cercarial shedding and the cercarial suspension was then collected. The 
cercariae were rinsed (x 3) with cold HBSS to detach the tails from the heads. The NTS were 
incubated overnight in culture medium and employed the following day. The test 
compounds and controls were dissolved in DMSO to a concentration of 10 mM. One 
hundred NTS were incubated in a 96-well plate with culture medium and the test compound 
to make up a final well volume of 250 μL. The culture medium was comprised of a mixture 
of medium 199 supplemented with 5% fetal calf serum and 1% penicillin/streptomycin. The 
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test compounds were assessed in triplicate at a concentration of 10 μM with NTS incubated 
in ≤ 1% DMSO serving as a control. The NTS were incubated at 37 °C and 5% CO2 for up to 72 
h. Thereafter, the effects of the compounds on NTS were evaluated microscopically using a 
scale from 3 (normal activity and morphological alteration) to 0 (dead).  
6.2.3.2.2 Adult S. mansoni Worms 
The adult schistosomes were obtained by subcutaneously infecting mice with 80−100 
cercariae. After 7 – 8 weeks, mice were euthanized with CO2 and the worms collected from 
the hepatic portal and mesenteric veins. In each well of the 24-well plate comprised of two 
pairs of adult worms incubated with 2 mL culture medium and the test compound. The 
culture medium was made up of RPMI 1640 supplemented with 5% fetal calf serum and a 
1% penicillin/streptomycin mixture. Test compounds with > 70% activity against NTS were 
tested against adult worms at 10 μM with incubation at < 1% DMSO used as a control. The 
worms were incubated at 37 °C and 5% CO2 for up to 72 h. Thereafter, the effects of the 
compounds on adult worms were evaluated microscopically using a scale from 3 (normal 
activity and morphological alteration) to 0 (dead).  
6.2.3.3 Gametocytocidal Activity 
The luciferase reporter assay was employed for accurate, reliable and quantifiable 
evaluation of the stage-specific action of gametocytocidal compounds against both the early 
and late gametocyte marker cell line NF54-PfS16-GFP-Luc. Drug assays were carried out on 
day 5 and 10 (representing > 90% of either early stage I/II/III or mature stage IV/V 
gametocytes, respectively). In each case, assays were set up using a 2 to 3% 
gametocytaemia, 1.5% haematocrit culture and 48 h drug pressure in a gas chamber (90% 
N2, 5% O2, and 5% CO2) at 37 °C. Luciferase activity was determined in 30 μl parasite lysates 
by adding 30 μl luciferin substrate (Promega Luciferase Assay System) at room temperature 
and detection of resultant bioluminescence at an integration constant of 10 s with the 
GloMax® Explorer Detection System with Instinct® Software. Methylene blue and 
MMV390048 are the controls whose % inhibitions of gametocyte viability were assessed at 
1 μM.  
 
 
6.2.4 β-Hematin inhibition activity 
Stock solutions of controls and test compounds were prepared using DMSO to make up 20 
mM. A solution composed of water/305.5 μM NP40/DMSO at a v/v ratio of 70%/20%/10%, 
respectively was added to every well in columns 1-11 while 140 μL of water and 40 μL of 
305.5 μM NP40 were added to column 12 to mediate the formation of β-haematin. 20 μL of 
the 20 mM test compounds were added to column 12 and 100 μL of this solution was 
serially diluted to column 2, with column 1 left as a blank (0 μM of compound). Hematin 
suspension was prepared by adding 178.8 μL aliquot of hematin stock to 20 ml of 1 M 
acetate buffer, pH 4.9 and 100 μL of the suspension was added into each well. 36  
Plates were then incubated for ±5 h at 37 °C after which 32 μL of pyridine solution (20% 
water, 20% acetone, 10% 2M HEPES buffer (pH 7.4), 50% pyridine) was added. A volume of 
60 μL of acetone was added to all the wells, plates were read at 405 nm and IC50 values 
were plotted using GraphPad. 
6.2.5 Turbidimetric Solubility 
Target compounds were dissolved in appropriate volumes of DMSO to make 10 mM stock 
solutions. Serial dilutions were then prepared on 96-well plates from a concentration range 
of 0.25 mM to 10 mM, with a blank well of 0 mM included as a reference. This was repeated 
three times for each sample on the pre-dilution plate. From each pre-dilution well, 
secondary dilutions of the samples in DMSO and 0.01 M phosphate-buffered saline (PBS, pH 
7.4) were then prepared on a second 96-well plate, the turbidimetric assay plate. This plate 
set up was also done in triplicate. The samples on the turbidimetric plate were prepared 
such that the final sample concentrations ranged from 0 to 200 µM.  
The turbidimetric assay plate was incubated for 2 h at room temperature. After incubation, 
absorbance at 620 nm was determined using a SpectraMax 340 PC384 microplate reader. 
Absorbance from the wells containing 100% DMSO and 2% v/v PBS in DMSO were blank 
readings. The absorbance versus concentration curves were plotted giving the solubility of 
the different test compounds. This is evident on the graph where the PBS curve deviates 
from the DMSO curve (baseline) due to an increase in absorbance readings. 
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